Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 552 articles:
HTML format
Text format



Single Articles


    March 2019
  1. RATNER E, Bala M, Louie-Gao M, Aydin E, et al
    Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    Gynecol Oncol. 2019 Mar 12. pii: S0090-8258(19)30152.
    PubMed     Text format     Abstract available


  2. LAVIE O, Chetrit A, Novikov I, Sadetzki S, et al
    Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30132.
    PubMed     Text format     Abstract available


  3. PRESCOTT LS, Taylor JS, Enbaya A, Marten CA, et al
    Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30156.
    PubMed     Text format     Abstract available


  4. RUENGKHACHORN I, Phithakwatchara N, Viriyapak B, Sangkarat S, et al
    Comparison of oncologic outcomes of unanticipated cervical carcinoma in women undergoing inadvertent simple hysterectomy and those undergoing surgical treatment after preoperative diagnosis.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30135.
    PubMed     Text format     Abstract available


  5. MORA PAR, Sun SY, Velarde GC, Filho JR, et al
    Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
    Gynecol Oncol. 2019 Mar 8. pii: S0090-8258(19)30153.
    PubMed     Text format     Abstract available


  6. MURAKAMI R, Matsumura N, Michimae H, Tanabe H, et al
    The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology G
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30120.
    PubMed     Text format     Abstract available


  7. FELIP I, Moiola CP, Megino-Luque C, Lopez-Gil C, et al
    Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30150.
    PubMed     Text format     Abstract available


  8. DOO DW, Kirkland CT, Griswold LH, McGwin G, et al
    Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution.
    Gynecol Oncol. 2019 Mar 6. pii: S0090-8258(19)30149.
    PubMed     Text format     Abstract available


  9. SON JH, Kim J, Shim J, Kong TW, et al
    Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision.
    Gynecol Oncol. 2019 Mar 4. pii: S0090-8258(19)30139.
    PubMed     Text format     Abstract available


  10. MERT I, Kumar A, Torres D, Huang Y, et al
    Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
    Gynecol Oncol. 2019 Mar 2. pii: S0090-8258(19)30128.
    PubMed     Text format     Abstract available


  11. BOGANI G, Mariani A, Paolini B, Ditto A, et al
    Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.
    Gynecol Oncol. 2019 Mar 1. pii: S0090-8258(19)30137.
    PubMed     Text format     Abstract available


  12. MOSS HA, Melamed A, Wright JD
    Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research.
    Gynecol Oncol. 2019;152:533-539.
    PubMed     Text format     Abstract available


  13. CALO C, Elliott JO, Clements A, Reid G, et al
    Cervical cancer radiation therapy compliance rates based on location of radiation therapy.
    Gynecol Oncol. 2019;152:528-532.
    PubMed     Text format     Abstract available


  14. ZAKEM SJ, Robin TP, Smith DE, Amini A, et al
    Evolving trends in the management of high-intermediate risk endometrial cancer in the United States.
    Gynecol Oncol. 2019;152:522-527.
    PubMed     Text format     Abstract available


  15. GRESSEL GM, Dioun SM, Richley M, Lounsbury DW, et al
    Utilizing the Patient Reported Outcomes Measurement Information System (PROMIS(R)) to increase referral to ancillary support services for severely symptomatic patients with gynecologic cancer.
    Gynecol Oncol. 2019;152:509-513.
    PubMed     Text format     Abstract available


  16. MEYER LA, Shi Q, Lasala J, Iniesta MD, et al
    Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
    Gynecol Oncol. 2019;152:501-508.
    PubMed     Text format     Abstract available


  17. WANG XS, Shi Q, Williams LA, Cleeland CS, et al
    Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).
    Gynecol Oncol. 2019;152:492-500.
    PubMed     Text format     Abstract available


  18. KUMAR A, Nesbitt KM, Bakkum-Gamez JN
    Quality improvement in gynecologic oncology: Current successes and future promise.
    Gynecol Oncol. 2019;152:486-491.
    PubMed     Text format     Abstract available


  19. NGUYEN JMV, Sadeghi M, Gien LT, Covens A, et al
    Impact of a preventive bundle to reduce surgical site infections in gynecologic oncology.
    Gynecol Oncol. 2019;152:480-485.
    PubMed     Text format     Abstract available


  20. VELENTZIS LS, Smith MA, Simms KT, Lew JB, et al
    Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.
    Gynecol Oncol. 2019;152:465-471.
    PubMed     Text format     Abstract available


  21. KWON JS, Tinker AV, Hanley GE, Pansegrau G, et al
    BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2019;152:459-464.
    PubMed     Text format     Abstract available


  22. TAYLOR JS, Zhang N, Rajan SS, Chavez-MacGregor M, et al
    How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.
    Gynecol Oncol. 2019;152:452-458.
    PubMed     Text format     Abstract available


  23. FOOTE JR, Secord AA, Liang MI, Ehrisman JA, et al
    Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2019;152:445-451.
    PubMed     Text format     Abstract available


  24. SUIDAN RS, He W, Sun CC, Zhao H, et al
    National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2019;152:439-444.
    PubMed     Text format     Abstract available


    February 2019
  25. BROOKS RA, Tritchler DS, Darcy KM, Lankes HA, et al
    GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2019 Feb 28. pii: S0090-8258(19)30138.
    PubMed     Text format     Abstract available


  26. TIMMERMANS M, van der Hel O, Sonke GS, Van de Vijver KK, et al
    The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30129.
    PubMed     Text format     Abstract available


  27. ARQUIETTE JM, Moss HA, Truong T, Pieper CF, et al
    Impact of a documentation intervention on health-assessment metrics on an inpatient gynecologic oncology service.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30119.
    PubMed     Text format     Abstract available


  28. BARRINGTON DA, Dilley SE, Smith HJ, Straughn JM Jr, et al
    Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2019 Feb 24. pii: S0090-8258(19)30123.
    PubMed     Text format     Abstract available


  29. JORGENSEN SL, Mogensen O, Petersen MA, Wu CS, et al
    New insights into early recovery after robotic surgery for endometrial cancer.
    Gynecol Oncol. 2019 Feb 23. pii: S0090-8258(19)30111.
    PubMed     Text format     Abstract available


  30. MORSE CB, Toukatly MN, Kilgore MR, Agnew KJ, et al
    Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    Gynecol Oncol. 2019 Feb 22. pii: S0090-8258(19)30121.
    PubMed     Text format     Abstract available


  31. HUEPENBECKER SP, Cusworth SE, Kuroki LM, Lu P, et al
    Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use.
    Gynecol Oncol. 2019 Feb 21. pii: S0090-8258(19)30127.
    PubMed     Text format     Abstract available


  32. MCGUIRE S, Kara B, Hart PC, Montag A, et al
    Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30059.
    PubMed     Text format     Abstract available


  33. MESQUITA KA, Alabdullah M, Griffin M, Toss MS, et al
    ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30124.
    PubMed     Text format     Abstract available


  34. MATSUO K, Machida H, Mandelbaum RS, Grubbs BH, et al
    Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30106.
    PubMed     Text format     Abstract available


  35. MATSUO K, Mandelbaum RS, Adams CL, Roman LD, et al
    Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study.
    Gynecol Oncol. 2019 Feb 18. pii: S0090-8258(19)30105.
    PubMed     Text format     Abstract available


  36. RODRIGUEZ-FREIXINOS V, Lheureux S, Mandilaras V, Clarke B, et al
    Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
    Gynecol Oncol. 2019 Feb 18. pii: S0090-8258(19)30108.
    PubMed     Text format     Abstract available


  37. EINSTEIN MH, Ndlovu N, Lee J, Stier EA, et al
    Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium.
    Gynecol Oncol. 2019 Feb 15. pii: S0090-8258(19)30065.
    PubMed     Text format     Abstract available


  38. VAN WALREE IC, Hamaker ME, van de Poll-Franse LV, Vos MC, et al
    Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.
    Gynecol Oncol. 2019 Feb 13. pii: S0090-8258(19)30104.
    PubMed     Text format     Abstract available


  39. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
    Gynecol Oncol. 2019 Feb 12. pii: S0090-8258(19)30113.
    PubMed     Text format     Abstract available


  40. LIANG J, Wolsiefer K, Zestcott CA, Chase D, et al
    Implicit bias toward cervical cancer: Provider and training differences.
    Gynecol Oncol. 2019 Feb 7. pii: S0090-8258(19)30055.
    PubMed     Text format     Abstract available


  41. SUSZYNSKA M, Klonowska K, Jasinska AJ, Kozlowski P, et al
    Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Gynecol Oncol. 2019 Feb 4. pii: S0090-8258(19)30069.
    PubMed     Text format     Abstract available


  42. HUTCHCRAFT ML, Smith B, McLaughlin EM, Hade EM, et al
    Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer.
    Gynecol Oncol. 2019 Feb 2. pii: S0090-8258(19)30068.
    PubMed     Text format     Abstract available


  43. LIM SL, Havrilesky LJ, Habib AS, Secord AA, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30067.
    PubMed     Text format     Abstract available


  44. VOGEL RI, Niendorf K, Petzel S, Lee H, et al
    A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30062.
    PubMed     Text format     Abstract available


  45. VASSILAKOS P, Poncet A, Catarino R, Viviano M, et al
    Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30064.
    PubMed     Text format     Abstract available


  46. ORSULIC S, Karlan BY
    Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?
    Gynecol Oncol. 2019;152:221-222.
    PubMed     Text format    


  47. SOONG TR, Howitt BE, Horowitz N, Nucci MR, et al
    The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.
    Gynecol Oncol. 2019;152:426-433.
    PubMed     Text format     Abstract available


  48. XIN W, Hua K, Ding J
    The way to display the chylous tubes and to prevent chylous leakage in laparoscopic para-aortic lymphadenectomy.
    Gynecol Oncol. 2019;152:434-435.
    PubMed     Text format    


  49. SMITH JA, Le T, Martin GA, Gaikwad A, et al
    Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
    Gynecol Oncol. 2019;152:265-269.
    PubMed     Text format     Abstract available


  50. FLEM KARLSEN K, McFadden E, Florenes VA, Davidson B, et al
    Soluble AXL is ubiquitously present in malignant serous effusions.
    Gynecol Oncol. 2019;152:408-415.
    PubMed     Text format     Abstract available


  51. XIA P, Huang M, Zhang Y, Xiong X, et al
    NCK1 promotes the angiogenesis of cervical squamous carcinoma via Rac1/PAK1/MMP2 signal pathway.
    Gynecol Oncol. 2019;152:387-395.
    PubMed     Text format     Abstract available


    January 2019
  52. HINCHCLIFF EM, Bednar EM, Lu KH, Rauh-Hain JA, et al
    Disparities in gynecologic cancer genetics evaluation.
    Gynecol Oncol. 2019 Jan 30. pii: S0090-8258(19)30066.
    PubMed     Text format     Abstract available


  53. NISHIO S, Mikami Y, Tokunaga H, Yaegashi N, et al
    Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.
    Gynecol Oncol. 2019 Jan 29. pii: S0090-8258(19)30063.
    PubMed     Text format     Abstract available


  54. HOSKINS P, Eccleston A, Hurry M, Dyer M, et al
    Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061.
    PubMed     Text format     Abstract available


  55. MODUGNO F, Goughnour SL, Wallack D, Edwards RP, et al
    Breastfeeding factors and risk of epithelial ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30060.
    PubMed     Text format     Abstract available


  56. CHOI HJ, Heo JH, Park JY, Jeong JY, et al
    A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30045.
    PubMed     Text format     Abstract available


  57. HURLEY RM, Wahner Hendrickson AE, Visscher DW, Ansell P, et al
    53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Gynecol Oncol. 2019 Jan 24. pii: S0090-8258(19)30058.
    PubMed     Text format     Abstract available


  58. YANG B, Xu Y, Zhu Q, Xie L, et al
    Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Gynecol Oncol. 2019 Jan 21. pii: S0090-8258(19)30056.
    PubMed     Text format     Abstract available


  59. HOLSCHNEIDER CH, Petereit DG, Chu C, Hsu IC, et al
    Brachytherapy: A critical component of primary radiation therapy for cervical cancer: For the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).
    Gynecol Oncol. 2019 Jan 17. pii: S0090-8258(18)31297.
    PubMed     Text format     Abstract available


  60. GOODMAN CR, Hatoum S, Seagle BL, Donnelly ED, et al
    Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer.
    Gynecol Oncol. 2019 Jan 16. pii: S0090-8258(19)30040.
    PubMed     Text format     Abstract available


  61. PRODROMIDOU A, Iavazzo C, Fotiou A, Psomiadou V, et al
    The application of fibrin sealant for the prevention of lymphocele after lymphadenectomy in patients with gynecological malignancies: A systematic review and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2019 Jan 16. pii: S0090-8258(19)30044.
    PubMed     Text format     Abstract available


  62. UPPENDAHL LD, Felices M, Bendzick L, Ryan C, et al
    Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039.
    PubMed     Text format     Abstract available


  63. DING J, Cheng XY, Liu S, Ji HY, et al
    Apatinib exerts anti-tumour effects on ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30043.
    PubMed     Text format     Abstract available


  64. CRIPE JC, Buchanan TR Jr, Kuroki LM, Wan L, et al
    Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30042.
    PubMed     Text format     Abstract available


  65. BREGAR A, Mojtahed A, Kilcoyne A, Kurra V, et al
    CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(18)31476.
    PubMed     Text format     Abstract available


  66. KIM SI, Cho JH, Seol A, Kim YI, et al
    Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(19)30041.
    PubMed     Text format     Abstract available


  67. OH SH, Park SJ, Lee EJ, Yim GW, et al
    Pelvic lymphadenectomy by vaginal natural orifice transluminal endoscopic surgery (vNOTES) for early-stage endometrial cancer.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(19)30002.
    PubMed     Text format    


  68. MCCUAIG JM, Tone AA, Maganti M, Romagnuolo T, et al
    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(18)31541.
    PubMed     Text format     Abstract available


  69. FABBRO M, Moore KN, Dorum A, Tinker AV, et al
    Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31473.
    PubMed     Text format     Abstract available


  70. WAGNER P, Kommoss FKF, Kommoss S, Hartkopf AD, et al
    Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease.
    Gynecol Oncol. 2019 Jan 8. pii: S0090-8258(18)31540.
    PubMed     Text format     Abstract available


  71. BONAZZOLI E, Cocco E, Lopez S, Bellone S, et al
    PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Gynecol Oncol. 2019 Jan 7. pii: S0090-8258(19)30004.
    PubMed     Text format     Abstract available


  72. MATSUO K, Hom MS, Yabuno A, Shida M, et al
    Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31534.
    PubMed     Text format     Abstract available


  73. JERZAK KJ, Duska L, MacKay HJ
    Endocrine therapy in endometrial cancer: An old dog with new tricks.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31518.
    PubMed     Text format     Abstract available


  74. YAO T, DeJong SR, McGree ME, Weaver AL, et al
    Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31539.
    PubMed     Text format     Abstract available


  75. FULK K, Milam MR, Li S, Yussuf A, et al
    Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31535.
    PubMed     Text format     Abstract available


  76. LONG B, Lilyquist J, Weaver A, Hu C, et al
    Cancer susceptibility gene mutations in type I and II endometrial cancer.
    Gynecol Oncol. 2019;152:20-25.
    PubMed     Text format     Abstract available


  77. RUSH CM, Goodfellow PJ
    Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution.
    Gynecol Oncol. 2019;152:1-2.
    PubMed     Text format    


  78. PARK SJ, Kim HS
    Laterally extended endopelvic resection with nephrectomy for vaginal cancer.
    Gynecol Oncol. 2019;152:218-219.
    PubMed     Text format    


  79. NICA A, Covens A, Vicus D, Kupets R, et al
    Sentinel lymph nodes in vulvar cancer: Management dilemmas in patients with positive nodes and larger tumors.
    Gynecol Oncol. 2019;152:94-100.
    PubMed     Text format     Abstract available


  80. SAND FL, Nielsen DMB, Frederiksen MH, Rasmussen CL, et al
    The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2019;152:208-217.
    PubMed     Text format     Abstract available


  81. LOOPIK DL, Bekkers RLM, Massuger LFAG, Melchers WJG, et al
    Justifying conservative management of CIN2 in women younger than 25years - A population-based study.
    Gynecol Oncol. 2019;152:82-86.
    PubMed     Text format     Abstract available


  82. SALCEDO MP, Sood AK, Dos Reis R, Ramalingam P, et al
    Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.
    Gynecol Oncol. 2019;152:101-105.
    PubMed     Text format     Abstract available


  83. SULLIVAN MW, Camacho FT, Mills AM, Modesitt SC, et al
    Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.
    Gynecol Oncol. 2019;152:119-126.
    PubMed     Text format     Abstract available


    December 2018
  84. LING DC, Vargo JA, Glaser SM, Kim H, et al
    Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer.
    Gynecol Oncol. 2018 Dec 29. pii: S0090-8258(18)31536.
    PubMed     Text format     Abstract available


  85. MATULONIS UA, Sill MW, Makker V, Mutch DG, et al
    A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Dec 23. pii: S0090-8258(18)31460.
    PubMed     Text format     Abstract available


  86. ZHANG L, Jiang Y, Lu X, Zhao H, et al
    Genomic characterization of cervical cancer based on human papillomavirus status.
    Gynecol Oncol. 2018 Dec 20. pii: S0090-8258(18)31516.
    PubMed     Text format     Abstract available


  87. ROSS JGC, Escamilla V, Lee NK, Diane Yamada S, et al
    Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.
    Gynecol Oncol. 2018 Dec 20. pii: S0090-8258(18)31470.
    PubMed     Text format     Abstract available


  88. RAUH-HAIN JA, Hidrue MK, Gaccione P, Melamed A, et al
    Variation in resource utilization associated with the surgical management of ovarian cancer.
    Gynecol Oncol. 2018 Dec 19. pii: S0090-8258(18)31513.
    PubMed     Text format     Abstract available


  89. MYSONA D, Pyrzak A, Purohit S, Zhi W, et al
    A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31515.
    PubMed     Text format     Abstract available


  90. CEPPI L, Galli F, Lamanna M, Magni S, et al
    Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31452.
    PubMed     Text format     Abstract available


  91. BULLS HW, Hoogland AI, Kennedy B, James BW, et al
    A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31458.
    PubMed     Text format     Abstract available


  92. NIE D, Gong H, Mao X, Li Z, et al
    Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31454.
    PubMed     Text format     Abstract available


  93. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    En bloc pelvic resection for ovarian carcinomatosis: Hudson procedure in 10 steps.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31471.
    PubMed     Text format    


  94. DAVIDSON BA, Broadwater G, Crim A, Boccacio R, et al
    Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31475.
    PubMed     Text format     Abstract available


  95. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31456.
    PubMed     Text format     Abstract available


  96. XIANG M, English DP, Kidd EA
    National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31472.
    PubMed     Text format     Abstract available


  97. NORQUIST BM
    Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31459.
    PubMed     Text format    


  98. BEDNAR EM, Sun CC, Camacho B, Terrell J, et al
    Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31457.
    PubMed     Text format     Abstract available


  99. LAW KE, Hildebrand EA, Hawthorne HJ, Hallbeck MS, et al
    A pilot study of non-routine events in gynecological surgery: Type, impact, and effect.
    Gynecol Oncol. 2018 Dec 6. pii: S0090-8258(18)31455.
    PubMed     Text format     Abstract available


  100. VARGA A, Piha-Paul S, Ott PA, Mehnert JM, et al
    Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
    Gynecol Oncol. 2018 Dec 3. pii: S0090-8258(18)31418.
    PubMed     Text format     Abstract available


  101. DUSKA LR
    Evolving times and paradigms in endometrial cancer: Incorporating and interpreting new data and technologic advances.
    Gynecol Oncol. 2018;151:393-394.
    PubMed     Text format    


  102. GAFFNEY DK, Hashibe M, Kepka D, Maurer KA, et al
    Too many women are dying from cervix cancer: Problems and solutions.
    Gynecol Oncol. 2018;151:547-554.
    PubMed     Text format     Abstract available


  103. VAN DER LINDEN M, van Esch E, Bulten J, Dreef E, et al
    The immune cell infiltrate in the microenvironment of vulvar Paget disease.
    Gynecol Oncol. 2018;151:453-459.
    PubMed     Text format     Abstract available


    November 2018
  104. TORRES D, Kumar A, Bakkum-Gamez JN, Weaver AL, et al
    Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31420.
    PubMed     Text format     Abstract available


  105. HAY CM, Donovan HS, Campbell GB, Taylor SE, et al
    Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance?
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31451.
    PubMed     Text format     Abstract available


  106. STANLEY B, Hollis RL, Nunes H, Towler JD, et al
    Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
    Gynecol Oncol. 2018 Nov 27. pii: S0090-8258(18)31450.
    PubMed     Text format     Abstract available


  107. PENN CA, Kamdar NS, Morgan DM, Spencer RJ, et al
    Preoperatively predicting non-home discharge after surgery for gynecologic malignancy.
    Gynecol Oncol. 2018 Nov 26. pii: S0090-8258(18)31449.
    PubMed     Text format     Abstract available


  108. SUBRAMANIAM A, Einerson BD, Blanchard CT, Erickson BK, et al
    The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
    Gynecol Oncol. 2018 Nov 23. pii: S0090-8258(18)31405.
    PubMed     Text format     Abstract available


  109. ALBEESH R, Turgeon GA, Alfieri J, Mansure JJ, et al
    Adjuvant therapy in stage III endometrial cancer confined to the pelvis.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31364.
    PubMed     Text format     Abstract available


  110. FRIJSTEIN MM, Lok CAR, van Trommel NE, Ten Kate-Booij MJ, et al
    Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31416.
    PubMed     Text format     Abstract available


  111. WISWELL S, Bell JG, McHale J, Elliott JO, et al
    The effect of art therapy on the quality of life in patients with a gynecologic cancer receiving chemotherapy.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31446.
    PubMed     Text format     Abstract available


  112. WAGNER BE, Langstraat CL, McGree ME, Weaver AL, et al
    Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422.
    PubMed     Text format     Abstract available


  113. JAVELLANA M, Hoppenot C, Lengyel E
    The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404.
    PubMed     Text format     Abstract available


  114. BOLAND JL, Zhou Q, Martin M, Callahan MK, et al
    Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
    Gynecol Oncol. 2018 Nov 20. pii: S0090-8258(18)31445.
    PubMed     Text format     Abstract available


  115. SANJIDA S, Janda M, McPhail SM, Kissane D, et al
    How many patients enter endometrial cancer surgery with psychotropic medication prescriptions, and how many receive a new prescription perioperatively?
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31419.
    PubMed     Text format     Abstract available


  116. ZHU B, Pan Y, Zheng X, Zhang Q, et al
    A clinical, biologic and mechanistic analysis of the role of ZNF692 in cervical cancer.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31423.
    PubMed     Text format     Abstract available


  117. HEITZ F, Harter P, Avall-Lundqvist E, Reuss A, et al
    Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31406.
    PubMed     Text format     Abstract available


  118. PRADER S, Vollmar N, du Bois A, Heitz F, et al
    Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2018 Nov 18. pii: S0090-8258(18)31363.
    PubMed     Text format     Abstract available


  119. GONZALEZ MARTIN A, Oza AM, Embleton AC, Pfisterer J, et al
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31166.
    PubMed     Text format     Abstract available


  120. ZHANG Q, Wang C, Cliby WA
    Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415.
    PubMed     Text format     Abstract available


  121. ROMEO C, Joly F, Ray-Coquard I, El Kouri C, et al
    Non-pegylated liposomal doxorubicin (NPLD, Myocet(R))+carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31358.
    PubMed     Text format     Abstract available


  122. KOTOULA V, Lakis S, Tikas I, Giannoulatou E, et al
    Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417.
    PubMed     Text format     Abstract available


  123. SIN STK, Li Y, Liu M, Ma S, et al
    TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling.
    Gynecol Oncol. 2018 Nov 12. pii: S0090-8258(18)31354.
    PubMed     Text format     Abstract available


  124. SPEES LP, Wheeler SB, Varia M, Weinberger M, et al
    Evaluating the urban-rural paradox: The complicated relationship between distance and the receipt of guideline-concordant care among cervical cancer patients.
    Gynecol Oncol. 2018 Nov 12. pii: S0090-8258(18)31407.
    PubMed     Text format     Abstract available


  125. UPPAL S, Rebecca Liu J, Kevin Reynolds R, Rice LW, et al
    Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012-2015).
    Gynecol Oncol. 2018 Nov 10. pii: S0090-8258(18)31246.
    PubMed     Text format     Abstract available


  126. BUCKINGHAM L, Haggerty A, Graul A, Morgan M, et al
    Sexual function following hysterectomy for endometrial cancer: A five-year follow up investigation.
    Gynecol Oncol. 2018 Nov 9. pii: S0090-8258(18)31308.
    PubMed     Text format     Abstract available


  127. TORTORELLA L, Casarin J, Mara KC, Weaver AL, et al
    Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31350.
    PubMed     Text format     Abstract available


  128. KURNIT KC, Previs RA, Soliman PT, Westin SN, et al
    Prognostic factors impacting survival in early stage uterine carcinosarcoma.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31317.
    PubMed     Text format     Abstract available


  129. ASHLEY CW, Da Cruz Paula A, Kumar R, Mandelker D, et al
    Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31316.
    PubMed     Text format     Abstract available


  130. HALL E, Finch A, Jacobson M, Rosen B, et al
    Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31355.
    PubMed     Text format     Abstract available


  131. ZHONG Q, Hu Z, Li Q, Yi T, et al
    Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31310.
    PubMed     Text format     Abstract available


  132. TURASHVILI G, Gomez-Hidalgo NR, Flynn J, Gonen M, et al
    Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
    Gynecol Oncol. 2018 Nov 6. pii: S0090-8258(18)31315.
    PubMed     Text format     Abstract available


  133. LEE JY, Park JY, Park SY, Lee JW, et al
    Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31314.
    PubMed     Text format     Abstract available


  134. MULLEN MM, Kuroki LM, Thaker PH
    Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31306.
    PubMed     Text format     Abstract available


  135. SPENCER RJ, Rice LW, Ye C, Woo K, et al
    Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores.
    Gynecol Oncol. 2018 Nov 4. pii: S0090-8258(18)31302.
    PubMed     Text format     Abstract available


  136. SELLA T, Stone RM
    The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.
    Gynecol Oncol. 2018;151:187-189.
    PubMed     Text format    


  137. LEEMAN A, Ebisch RMF, Kasius A, Bosgraaf RP, et al
    Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
    Gynecol Oncol. 2018;151:311-318.
    PubMed     Text format     Abstract available


  138. FIANO V, Trevisan M, Fasanelli F, Grasso C, et al
    Methylation in host and viral genes as marker of aggressiveness in cervical lesions: Analysis in 543 unscreened women.
    Gynecol Oncol. 2018;151:319-326.
    PubMed     Text format     Abstract available


  139. SPAANS VM, Scheunhage DA, Barzaghi B, de Kroon CD, et al
    Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival.
    Gynecol Oncol. 2018;151:196-201.
    PubMed     Text format     Abstract available


    October 2018
  140. MATSUO K, Machida H, Mandelbaum RS, Konishi I, et al
    Validation of the 2018 FIGO cervical cancer staging system.
    Gynecol Oncol. 2018 Oct 30. pii: S0090-8258(18)31309.
    PubMed     Text format     Abstract available


  141. WANG Y, Jiang J, He L, Gong G, et al
    Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.
    Gynecol Oncol. 2018 Oct 29. pii: S0090-8258(18)31313.
    PubMed     Text format     Abstract available


  142. DUSKA LR, Suh DH, Wilson M, Diane Yamada S, et al
    International Gynecologic Cancer Society (IGCS) 2018: Meeting report.
    Gynecol Oncol. 2018 Oct 27. pii: S0090-8258(18)31301.
    PubMed     Text format    


  143. TANGEN IL, Fasmer KE, Konings GF, Jochems A, et al
    Blood steroids are associated with prognosis and fat distribution in endometrial cancer.
    Gynecol Oncol. 2018 Oct 26. pii: S0090-8258(18)31307.
    PubMed     Text format     Abstract available


  144. DING L, Ding Y, Kong X, Wu J, et al
    Dysregulation of Kruppel-like factor 12 in the development of endometrial cancer.
    Gynecol Oncol. 2018 Oct 25. pii: S0090-8258(18)31311.
    PubMed     Text format     Abstract available


  145. HANSEN JM, Sood AK, Coleman RL, Westin SN, et al
    Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31299.
    PubMed     Text format     Abstract available


  146. HINCHCLIFF E, Hong D, Le H, Chisholm G, et al
    Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31287.
    PubMed     Text format     Abstract available


  147. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303.
    PubMed     Text format    


  148. CIBULA D, Abu-Rustum NR, Fischerova D, Pather S, et al
    Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature.
    Gynecol Oncol. 2018 Oct 20. pii: S0090-8258(18)31298.
    PubMed     Text format     Abstract available


  149. TA RM, Hecht JL, Lin DI
    Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Gynecol Oncol. 2018 Oct 16. pii: S0090-8258(18)31291.
    PubMed     Text format     Abstract available


  150. HUANG C, Lu H, Li J, Xie X, et al
    SOX2 regulates radioresistance in cervical cancer via the hedgehog signaling pathway.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31284.
    PubMed     Text format     Abstract available


  151. TANNER EJ, Filippova OT, Gardner GJ, Long Roche KC, et al
    A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31285.
    PubMed     Text format     Abstract available


  152. SAPIENZA LG, Jhingran A, Kollmeier MA, Lin LL, et al
    Decrease in uterine perforations with ultrasound image-guided applicator insertion in intracavitary brachytherapy for cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2018 Oct 14. pii: S0090-8258(18)31290.
    PubMed     Text format     Abstract available


  153. CARTER NJ, Marshall ML, Susswein LR, Zorn KK, et al
    Germline pathogenic variants identified in women with ovarian tumors.
    Gynecol Oncol. 2018 Oct 12. pii: S0090-8258(18)31249.
    PubMed     Text format     Abstract available


  154. CIBULA D, McCluggage WG
    Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions.
    Gynecol Oncol. 2018 Oct 11. pii: S0090-8258(18)31286.
    PubMed     Text format     Abstract available


  155. SALINARO JR, Puechl AM, Havrilesky LJ, Davidson BA, et al
    Gender trends in gynecologic oncology authorship: Implications for the critical evaluation of gender distribution in academic rank and leadership positions.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31288.
    PubMed     Text format     Abstract available


  156. KIM HS, Kim JY, Lee YJ, Kim SH, et al
    Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31153.
    PubMed     Text format     Abstract available


  157. NAUMANN RW, Morris JC, Tait DL, Higgins RV, et al
    Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31282.
    PubMed     Text format     Abstract available


  158. MONK BJ, Kauderer JT, Moxley KM, Bonebrake AJ, et al
    A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31281.
    PubMed     Text format     Abstract available


  159. BELUR NAGARAJ A, Joseph P, Kovalenko O, Wang Q, et al
    Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
    Gynecol Oncol. 2018 Oct 6. pii: S0090-8258(18)31238.
    PubMed     Text format     Abstract available


  160. WANG J, Dean DC, Hornicek FJ, Shi H, et al
    RNA sequencing (RNA-Seq) and its application in ovarian cancer.
    Gynecol Oncol. 2018 Oct 5. pii: S0090-8258(18)31283.
    PubMed     Text format     Abstract available


  161. RASH JK, Lyle KD, Jairam-Thodla A, Ioffe Y, et al
    Delivery of gynecologic oncology care: Optimizing scope of advanced practice providers to enhance patient care: A Society of Gynecologic Oncology Position Paper.
    Gynecol Oncol. 2018 Oct 4. pii: S0090-8258(18)31237.
    PubMed     Text format    


  162. WANG W, Zou W, Liu JR
    Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Gynecol Oncol. 2018;151:1-3.
    PubMed     Text format    


  163. ALOISI A, Casanova JM, Tseng JH, Seader KA, et al
    Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.
    Gynecol Oncol. 2018 Oct 1. pii: S0090-8258(18)31240.
    PubMed     Text format     Abstract available


  164. MARTINEZ-GOMEZ C, Angeles MA, Martinez A, Ferron G, et al
    Creation of a Miami Pouch in 10 logical steps.
    Gynecol Oncol. 2018;151:178-179.
    PubMed     Text format    


  165. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography.
    Gynecol Oncol. 2018;151:180-181.
    PubMed     Text format    


  166. RODRIGUES LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, et al
    Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajos region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors.
    Gynecol Oncol. 2018;151:102-110.
    PubMed     Text format     Abstract available


  167. HORNE ZD, Dohopolski MJ, Pradhan D, Bhargava R, et al
    Human papillomavirus infection mediates response and outcome of vulvar squamous cell carcinomas treated with radiation therapy.
    Gynecol Oncol. 2018;151:96-101.
    PubMed     Text format     Abstract available


    September 2018
  168. ELNAGGAR AC, Hade EM, O'Malley DM, Liang MI, et al
    Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
    Gynecol Oncol. 2018 Sep 30. pii: S0090-8258(18)31233.
    PubMed     Text format     Abstract available


  169. NASSER S, Lathouras K, Nixon K, Campbell J, et al
    Impact of right upper quadrant cytoreductive techniques with extensive liver mobilization on postoperative hepatic function and risk of liver failure in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 29. pii: S0090-8258(18)31247.
    PubMed     Text format     Abstract available


  170. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Left cardiophrenic lymph node resection for advanced ovarian cancer with adhesion to the thoracic cavity.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31241.
    PubMed     Text format    


  171. ZHANG L, Xu XQ, Hu SY, Chen F, et al
    Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31231.
    PubMed     Text format     Abstract available


  172. SHENOLIKAR R, Durden E, Meyer N, Lenhart G, et al
    Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31176.
    PubMed     Text format     Abstract available


  173. MANGILI G, Cioffi R, Danese S, Frigerio L, et al
    Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31244.
    PubMed     Text format     Abstract available


  174. WANG W, Zhang F, Hu K, Hou X, et al
    Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer.
    Gynecol Oncol. 2018 Sep 25. pii: S0090-8258(18)31243.
    PubMed     Text format     Abstract available


  175. LIM SL, Moss HA, Secord AA, Lee PS, et al
    Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31239.
    PubMed     Text format     Abstract available


  176. NIEMI RJ, Roine AN, Eraviita E, Kumpulainen PS, et al
    FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31235.
    PubMed     Text format     Abstract available


  177. TAYLOR JS, He W, Harrison R, Zhao H, et al
    Disparities in treatment and survival among elderly ovarian cancer patients.
    Gynecol Oncol. 2018 Sep 22. pii: S0090-8258(18)31171.
    PubMed     Text format     Abstract available


  178. HANNIBAL CG, Dehlendorff C, Kjaer SK
    Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31242.
    PubMed     Text format     Abstract available


  179. ZIVANOVIC O, Chi DS, Filippova O, Randall LM, et al
    It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31218.
    PubMed     Text format     Abstract available


  180. HUA W, Zhao Y, Jin X, Yu D, et al
    METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31234.
    PubMed     Text format     Abstract available


  181. BOITANO TKL, Smith HJ, Rushton T, Johnston MC, et al
    Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.
    Gynecol Oncol. 2018 Sep 20. pii: S0090-8258(18)31220.
    PubMed     Text format     Abstract available


  182. ROBERTS ME, Aynardi JT, Chu CS
    Uterine leiomyosarcoma: A review of the literature and update on management options.
    Gynecol Oncol. 2018 Sep 20. pii: S0090-8258(18)31221.
    PubMed     Text format     Abstract available


  183. DOWDY SC, Cliby WA, Famuyide AO
    Quality indicators in gynecologic oncology.
    Gynecol Oncol. 2018 Sep 13. pii: S0090-8258(18)31175.
    PubMed     Text format    


  184. WANG D, Cao D, Jia C, Huang H, et al
    Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors.
    Gynecol Oncol. 2018 Sep 12. pii: S0090-8258(18)31214.
    PubMed     Text format     Abstract available


  185. ODA K, Hamanishi J, Matsuo K, Hasegawa K, et al
    Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Gynecol Oncol. 2018 Sep 11. pii: S0090-8258(18)31174.
    PubMed     Text format     Abstract available


  186. JAZAERI A, Coleman RL, Sood AK, Frumovitz MM, et al
    A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
    Gynecol Oncol. 2018 Sep 10. pii: S0090-8258(18)31167.
    PubMed     Text format     Abstract available


  187. AZIZ D, Etemadmoghadam D, Caldon CE, Au-Yeung G, et al
    19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Gynecol Oncol. 2018 Sep 9. pii: S0090-8258(18)31169.
    PubMed     Text format     Abstract available


  188. ZHAO H, Yu H, Zheng J, Ning N, et al
    Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31162.
    PubMed     Text format     Abstract available


  189. CONNOR JP, O'Shea A, McCool K, Sampene E, et al
    Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31170.
    PubMed     Text format     Abstract available


  190. MATSUO K, Machida H, Mandelbaum RS, Ragab OM, et al
    Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31165.
    PubMed     Text format     Abstract available


  191. RAJKUMAR S, Polson A, Nath R, Lane G, et al
    Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31172.
    PubMed     Text format     Abstract available


  192. GHELARDI A, Parazzini F, Martella F, Pieralli A, et al
    SPERANZA project: HPV vaccination after treatment for CIN2.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31163.
    PubMed     Text format    


  193. KIM HJ, Chang JS, Koom WS, Lee KC, et al
    Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer.
    Gynecol Oncol. 2018 Sep 5. pii: S0090-8258(18)31158.
    PubMed     Text format     Abstract available


  194. SCURRY J, van Zyl B, Gulliver D, Otton G, et al
    Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31160.
    PubMed     Text format     Abstract available


  195. SIMONDS HM, Botha MH, Neugut AI, Van Der Merwe FH, et al
    Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31168.
    PubMed     Text format     Abstract available


  196. LIU Y, Weber Z, San Lucas FA, Deshpande A, et al
    Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31173.
    PubMed     Text format     Abstract available


  197. MILLS KA, Roach ST, Quinn JM, Guo L, et al
    SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
    Gynecol Oncol. 2018 Sep 3. pii: S0090-8258(18)31097.
    PubMed     Text format     Abstract available


  198. TSENG JH, Cowan RA, Afonso AM, Zhou Q, et al
    Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 2. pii: S0090-8258(18)31154.
    PubMed     Text format     Abstract available


  199. YEN TT, Miyamoto T, Asaka S, Chui MH, et al
    Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
    Gynecol Oncol. 2018;150:426-431.
    PubMed     Text format     Abstract available


  200. DE VINCENZO R, Tortorella L, Ricci C, Cavaliere AF, et al
    Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome.
    Gynecol Oncol. 2018;150:398-405.
    PubMed     Text format     Abstract available


  201. DEL CARMEN MG, Pareja R, Melamed A, Rodriguez J, et al
    Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.
    Gynecol Oncol. 2018;150:406-411.
    PubMed     Text format     Abstract available


  202. ZIEBA S, Kowalik A, Zalewski K, Rusetska N, et al
    Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Gynecol Oncol. 2018;150:552-561.
    PubMed     Text format     Abstract available


    August 2018
  203. TEW WP, Sill MW, Walker JL, Secord AA, et al
    Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31157.
    PubMed     Text format     Abstract available


  204. SCHLAPPE BA, Weaver AL, Ducie JA, Eriksson AGZ, et al
    Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152.
    PubMed     Text format     Abstract available


  205. BOARDMAN CH, Brady WE, Dizon DS, Kunos CA, et al
    A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologi
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31095.
    PubMed     Text format     Abstract available


  206. KIM SR, Pina A, Albert A, McAlpine J, et al
    Does MMR status in endometrial cancer influence response to adjuvant therapy?
    Gynecol Oncol. 2018 Aug 29. pii: S0090-8258(18)31151.
    PubMed     Text format     Abstract available


  207. SHINDE A, Li R, Amini A, Chen YJ, et al
    Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31159.
    PubMed     Text format     Abstract available


  208. VAN NIEUWENHUYSEN E, Busschaert P, Neven P, Han SN, et al
    The genetic landscape of 87 ovarian germ cell tumors.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31130.
    PubMed     Text format     Abstract available


  209. LYCKE M, Kristjansdottir B, Sundfeldt K
    A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31155.
    PubMed     Text format     Abstract available


  210. DIOUN S, Jorgensen JR, Miller EM, Tymon-Rosario J, et al
    Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31150.
    PubMed     Text format     Abstract available


  211. YUK JS, Lee JH
    Six-year survival of patients with unsuspected uterine malignancy after laparoscopic versus laparotomic myomectomy: An 11-year national retrospective cohort study.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31156.
    PubMed     Text format     Abstract available


  212. RAUH-HAIN JA, Brewster WR, Behbakht K
    Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31149.
    PubMed     Text format    


  213. CHANG JS, Kim SW, Kim YJ, Kim JY, et al
    Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31129.
    PubMed     Text format     Abstract available


  214. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Resection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver.
    Gynecol Oncol. 2018 Aug 20. pii: S0090-8258(18)31134.
    PubMed     Text format     Abstract available


  215. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Aug 19. pii: S0090-8258(18)31085.
    PubMed     Text format     Abstract available


  216. TSENG JH, Cowan RA, Zhou Q, Iasonos A, et al
    Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Gynecol Oncol. 2018 Aug 17. pii: S0090-8258(18)31131.
    PubMed     Text format     Abstract available


  217. SON JH, Lee JH, Jung JA, Kong TW, et al
    Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2018 Aug 16. pii: S0090-8258(18)31098.
    PubMed     Text format     Abstract available


  218. BARBER EL, Rossi EC, Alexander A, Bilimoria K, et al
    Benign hysterectomy performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality?
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31127.
    PubMed     Text format     Abstract available


  219. PERES LC, Cushing-Haugen KL, Anglesio M, Wicklund K, et al
    Histotype classification of ovarian carcinoma: A comparison of approaches.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31133.
    PubMed     Text format     Abstract available


  220. ULM MA, ElNaggar AC, Tillmanns TD
    Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31132.
    PubMed     Text format     Abstract available


  221. CONNOR EV, Newlin EM, Jelovsek JE, AlHilli MM, et al
    Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
    Gynecol Oncol. 2018 Aug 11. pii: S0090-8258(18)31128.
    PubMed     Text format     Abstract available


  222. BISCH SP, Wells T, Gramlich L, Faris P, et al
    Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes.
    Gynecol Oncol. 2018 Aug 9. pii: S0090-8258(18)31096.
    PubMed     Text format     Abstract available


  223. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Corrigendum to "Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells" [Gyncol. Oncol. 144 (2017) 598-606].
    Gynecol Oncol. 2018 Aug 7. pii: S0090-8258(18)31079.
    PubMed     Text format    


  224. MOORE KN, O'Malley DM, Vergote I, Martin LP, et al
    Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2018 Aug 6. pii: S0090-8258(18)31081.
    PubMed     Text format     Abstract available


  225. MALLEN A, Soong TR, Townsend MK, Wenham RM, et al
    Surgical prevention strategies in ovarian cancer.
    Gynecol Oncol. 2018 Aug 4. pii: S0090-8258(18)31094.
    PubMed     Text format     Abstract available


  226. LI A, Xie R, Zhi Q, Deng Y, et al
    BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31088.
    PubMed     Text format     Abstract available


  227. WORTMAN BG, Bosse T, Nout RA, Lutgens LCHW, et al
    Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31084.
    PubMed     Text format     Abstract available


  228. PINTO MP, Balmaceda C, Bravo ML, Kato S, et al
    Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31089.
    PubMed     Text format     Abstract available


  229. WILFORD J, Osann K, Hsieh S, Monk B, et al
    Validation of PROMIS emotional distress short form scales for cervical cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31086.
    PubMed     Text format     Abstract available


  230. LEE J, Gubernick LR, Brodsky AL, Fehniger JE, et al
    Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer.
    Gynecol Oncol. 2018 Aug 1. pii: S0090-8258(18)31087.
    PubMed     Text format     Abstract available


  231. LEVINE DA
    The limits of aggressive surgical cytoreduction.
    Gynecol Oncol. 2018;150:205-206.
    PubMed     Text format    


  232. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    Laparoscopic hand-assisted Miami Pouch after pelvic exenteration in 10 steps.
    Gynecol Oncol. 2018;150:389-390.
    PubMed     Text format     Abstract available


  233. MANNING-GEIST BL, Hicks-Courant K, Gockley AA, Clark RM, et al
    Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Gynecol Oncol. 2018;150:233-238.
    PubMed     Text format     Abstract available


  234. SHAH R, Xia C, Krailo M, Amatruda JF, et al
    Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
    Gynecol Oncol. 2018;150:253-260.
    PubMed     Text format     Abstract available


    July 2018
  235. BEHBAKHT K, Cohn DE, Straughn JM Jr
    Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
    Gynecol Oncol. 2018 Jul 30. pii: S0090-8258(18)31083.
    PubMed     Text format    


  236. SONG M, Kumaran MN, Gounder M, Gibbon DG, et al
    Phase I trial of selenium plus chemotherapy in gynecologic cancers.
    Gynecol Oncol. 2018 Jul 29. pii: S0090-8258(18)31014.
    PubMed     Text format     Abstract available


  237. VERGOTE I, von Moos R, Manso L, Van Nieuwenhuysen E, et al
    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
    Gynecol Oncol. 2018 Jul 27. pii: S0090-8258(18)31082.
    PubMed     Text format     Abstract available


  238. MATSUO K, Blake EA, Machida H, Mandelbaum RS, et al
    Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31080.
    PubMed     Text format     Abstract available


  239. MEAGHER NS, Schuster K, Voss A, Budden T, et al
    Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31077.
    PubMed     Text format     Abstract available


  240. WEBSTER EM, Burke WM, Ware HM, Jones BA, et al
    Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31064.
    PubMed     Text format     Abstract available


  241. NISHIO S, Shimokawa M, Tasaki K, Nasu H, et al
    A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31078.
    PubMed     Text format     Abstract available


  242. CHAN JK, Gardner AB, Mann AK, Kapp DS, et al
    Hospital-acquired conditions after surgery for gynecologic cancer - An analysis of 82,304 patients.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31065.
    PubMed     Text format     Abstract available


  243. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma.
    Gynecol Oncol. 2018 Jul 19. pii: S0090-8258(18)31067.
    PubMed     Text format     Abstract available


  244. GREEN RW, Valentin L, Alcazar JL, Chiappa V, et al
    Endometrial cancer off-line staging using two-dimensional transvaginal ultrasound and three-dimensional volume contrast imaging: Intermethod agreement, interrater reliability and diagnostic accuracy.
    Gynecol Oncol. 2018 Jul 17. pii: S0090-8258(18)31009.
    PubMed     Text format     Abstract available


  245. BI Y, Verginadis II, Dey S, Lin L, et al
    Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Gynecol Oncol. 2018 Jul 16. pii: S0090-8258(18)31015.
    PubMed     Text format     Abstract available


  246. TIWARI R, Narayanan GS, Jayakumar V, Narayanan S, et al
    The promise of image-guided brachytherapy of better clinical outcomes in treatment of cervical cancer: Does it deliver? An Indian scenario.
    Gynecol Oncol. 2018 Jul 14. pii: S0090-8258(18)31068.
    PubMed     Text format     Abstract available


  247. GALINDO LJ, Hernandez-Beeftink T, Salas A, Jung Y, et al
    HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
    Gynecol Oncol. 2018 Jul 12. pii: S0090-8258(18)31063.
    PubMed     Text format     Abstract available


  248. BARNARD ME, Pyden A, Rice MS, Linares M, et al
    Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31016.
    PubMed     Text format     Abstract available


  249. TIMMERMANS M, van der Aa MA, Lalisang RI, Witteveen PO, et al
    Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31017.
    PubMed     Text format     Abstract available


  250. DENG K, Yang C, Tan Q, Song W, et al
    Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31004.
    PubMed     Text format     Abstract available


  251. XUE R, Cai X, Xu H, Wu S, et al
    The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: A meta-analysis.
    Gynecol Oncol. 2018 Jul 8. pii: S0090-8258(18)31018.
    PubMed     Text format     Abstract available


  252. BURGER RA, Deng W, Makker V, Collins Y, et al
    Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Jul 2. pii: S0090-8258(18)30999.
    PubMed     Text format     Abstract available


  253. SECORD AA, Previs RA, Nixon AB
    Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Gynecol Oncol. 2018;150:1-2.
    PubMed     Text format    


  254. CIUCCI A, Ferrandina G, Mascilini F, Filippetti F, et al
    Estrogen receptor beta: Potential target for therapy in adult granulosa cell tumors?
    Gynecol Oncol. 2018;150:158-165.
    PubMed     Text format     Abstract available


  255. NALDINI A, Vizzielli G, Perrone E, Gallotta V, et al
    Robotic video endoscopic inguinal lymphadenectomy (R-VEIL) for vulvar cancer with sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology.
    Gynecol Oncol. 2018;150:203-204.
    PubMed     Text format     Abstract available


  256. MARTINEZ-GOMEZ C, Angeles MA, Martinez A, Ferron G, et al
    Laparoscopic anterior pelvic exenteration in 10 steps.
    Gynecol Oncol. 2018;150:201-202.
    PubMed     Text format    


  257. LEES BF, Stewart TP, Rash JK, Baron SR, et al
    Abuse, cancer and sexual dysfunction in women: A potentially vicious cycle.
    Gynecol Oncol. 2018;150:166-172.
    PubMed     Text format     Abstract available


  258. CHARAKORN C, Thadanipon K, Chaijindaratana S, Rattanasiri S, et al
    The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2018;150:190-200.
    PubMed     Text format     Abstract available


    June 2018
  259. MEYER LA, He W, Sun CC, Zhao H, et al
    Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
    Gynecol Oncol. 2018 Jun 29. pii: S0090-8258(18)31002.
    PubMed     Text format     Abstract available


  260. ROGERI CD, Silveira HCS, Causin RL, Villa LL, et al
    Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30990.
    PubMed     Text format     Abstract available


  261. ZHANG XS, Zhang YM, Li B, Fan B, et al
    Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30988.
    PubMed     Text format     Abstract available


  262. VERDOODT F, Dehlendorff C, Friis S, Kjaer SK, et al
    Non-aspirin NSAID use and ovarian cancer mortality.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)31000.
    PubMed     Text format     Abstract available


  263. LEATH CA 3RD, Monk BJ
    Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.
    Gynecol Oncol. 2018 Jun 26. pii: S0090-8258(18)31005.
    PubMed     Text format     Abstract available


  264. GOCKLEY AA, Kolin DL, Awtrey CS, Lindeman NI, et al
    Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    Gynecol Oncol. 2018 Jun 21. pii: S0090-8258(18)30937.
    PubMed     Text format     Abstract available


  265. RAUH LA, Saks EJ, Nakad-Rodriguez D, Showalter TN, et al
    Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers.
    Gynecol Oncol. 2018 Jun 20. pii: S0090-8258(18)31001.
    PubMed     Text format     Abstract available


  266. NIEVES-NEIRA W, Kim JJ, Matei D
    Hormonal strategies in gynecologic cancer: Bridging biology and therapy.
    Gynecol Oncol. 2018 Jun 20. pii: S0090-8258(18)30947.
    PubMed     Text format    


  267. GEBHARDT BJ, Vargo JA, Kim H, Houser CJ, et al
    Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30987.
    PubMed     Text format     Abstract available


  268. ROSS MS, Burriss ME, Winger DG, Edwards RP, et al
    Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30984.
    PubMed     Text format     Abstract available


  269. CLARK RM, Rice LW, Del Carmen MG
    Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30985.
    PubMed     Text format     Abstract available


  270. URBAN RR, Pappas TC, Bullock RG, Munroe DG, et al
    Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30946.
    PubMed     Text format     Abstract available


  271. TORRES D, Wang C, Kumar A, Bakkum-Gamez JN, et al
    Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
    Gynecol Oncol. 2018 Jun 17. pii: S0090-8258(18)30944.
    PubMed     Text format     Abstract available


  272. CHAN JK, Brady W, Monk BJ, Brown J, et al
    A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30941.
    PubMed     Text format     Abstract available


  273. LI N, Zhan X, Zhan X
    The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30989.
    PubMed     Text format     Abstract available


  274. BODY N, Gregoire J, Renaud MC, Sebastianelli A, et al
    Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer.
    Gynecol Oncol. 2018 Jun 14. pii: S0090-8258(18)30943.
    PubMed     Text format     Abstract available


  275. GRAETZ I, Anderson JN, McKillop CN, Stepanski EJ, et al
    Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial.
    Gynecol Oncol. 2018 Jun 11. pii: S0090-8258(18)30983.
    PubMed     Text format     Abstract available


  276. BOLZE PA, Mathe M, Hajri T, You B, et al
    First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive.
    Gynecol Oncol. 2018 Jun 8. pii: S0090-8258(18)30942.
    PubMed     Text format     Abstract available


  277. MICHAEL STRAUGHN J JR, Boitano T, Smith HJ, Dilley SE, et al
    Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman.
    Gynecol Oncol. 2018 Jun 7. pii: S0090-8258(18)30923.
    PubMed     Text format     Abstract available


  278. BUDA A, Gasparri ML, Puppo A, Mereu L, et al
    Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy.
    Gynecol Oncol. 2018 Jun 7. pii: S0090-8258(18)30945.
    PubMed     Text format     Abstract available


  279. WOOLDERINK JM, De Bock GH, de Hullu JA, Hollema H, et al
    Characteristics of Lynch syndrome associated ovarian cancer.
    Gynecol Oncol. 2018 Jun 4. pii: S0090-8258(18)30240.
    PubMed     Text format     Abstract available


  280. STOLER MH, Wright TC Jr, Parvu V, Vaughan L, et al
    The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
    Gynecol Oncol. 2018;149:498-505.
    PubMed     Text format     Abstract available


    May 2018
  281. STOLNICU S, Barsan I, Hoang L, Patel P, et al
    Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV.
    Gynecol Oncol. 2018 May 30. pii: S0090-8258(18)30848.
    PubMed     Text format     Abstract available


  282. AREND RC, Jones BA, Martinez A, Goodfellow P, et al
    Endometrial cancer: Molecular markers and management of advanced stage disease.
    Gynecol Oncol. 2018 May 27. pii: S0090-8258(18)30902.
    PubMed     Text format     Abstract available


  283. LINDEMANN K, Gao B, Mapagu C, Fereday S, et al
    Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30907.
    PubMed     Text format     Abstract available


  284. GIANNOPOULOU L, Mastoraki S, Buderath P, Strati A, et al
    ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30922.
    PubMed     Text format     Abstract available


  285. YAGUR Y, Weitzner O, Gemer O, Lavie O, et al
    Postoperative radiation rates in stage IIA1 cervical cancer: Is surgical treatment justified? An Israeli Gynecologic Oncology Group Study.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30903.
    PubMed     Text format     Abstract available


  286. AHMED A, Deng W, Tew W, Bender D, et al
    Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30909.
    PubMed     Text format     Abstract available


  287. SALVO G, Frumovitz M, Pareja R, Lee J, et al
    Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 (>/=2cm) cervical cancer: Bridging the gap to fetal viability.
    Gynecol Oncol. 2018 May 24. pii: S0090-8258(18)30908.
    PubMed     Text format     Abstract available


  288. AGHAJANIAN C, Filiaci V, Dizon DS, Carlson JW, et al
    A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2018 May 24. pii: S0090-8258(18)30905.
    PubMed     Text format     Abstract available


  289. BAIOCCHI G, Mantoan H, Chen MJ, Faloppa CC, et al
    Uterine transposition after radical trachelectomy.
    Gynecol Oncol. 2018 May 23. pii: S0090-8258(18)30896.
    PubMed     Text format    


  290. MAYOR P, Starbuck K, Zsiros E
    Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
    Gynecol Oncol. 2018 May 23. pii: S0090-8258(18)30920.
    PubMed     Text format     Abstract available


  291. KALAMPOKAS E, Payne F, Gurumurthy M
    An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30910.
    PubMed     Text format     Abstract available


  292. MUELLER JJ, Schlappe BA, Kumar R, Olvera N, et al
    Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30895.
    PubMed     Text format     Abstract available


  293. KOTSOPOULOS J, Gronwald J, Karlan B, Rosen B, et al
    Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30898.
    PubMed     Text format     Abstract available


  294. VON GRUENIGEN VE, Huang HQ, Cella D, Zevon M, et al
    Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 May 17. pii: S0090-8258(18)30904.
    PubMed     Text format     Abstract available


  295. ROLSTON A, Spencer RJ, Kevin Reynolds R, Rice LW, et al
    Factors associated with outcomes and inpatient 90-day cost of care in endometrial cancer patients undergoing hysterectomy - implications for bundled care payments.
    Gynecol Oncol. 2018 May 16. pii: S0090-8258(18)30897.
    PubMed     Text format     Abstract available


  296. PHILP L, Jembere N, Wang L, Gao J, et al
    Pap tests in the diagnosis of cervical cancer: Help or hinder?
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30906.
    PubMed     Text format     Abstract available


  297. O'SHEA A, McCool K, Harrison R, Sampene E, et al
    Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30901.
    PubMed     Text format     Abstract available


  298. TSENG JH, Aloisi A, Sonoda Y, Gardner GJ, et al
    Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30849.
    PubMed     Text format     Abstract available


  299. FELIX AS, Sinnott JA, Vetter MH, Rhoades J, et al
    Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30893.
    PubMed     Text format     Abstract available


  300. RUSCITO I, Darb-Esfahani S, Kulbe H, Bellati F, et al
    The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30892.
    PubMed     Text format     Abstract available


  301. NASIOUDIS D, Mastroyannis SA, Albright BB, Haggerty AF, et al
    Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30845.
    PubMed     Text format     Abstract available


  302. DAVIS M, Strickland K, Easter SR, Worley M Jr, et al
    The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30887.
    PubMed     Text format     Abstract available


  303. BAERT T, Van Camp J, Vanbrabant L, Busschaert P, et al
    Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30891.
    PubMed     Text format     Abstract available


  304. YI Y, Bryce CL, Adambekov S, Edwards RP, et al
    Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage.
    Gynecol Oncol. 2018 May 7. pii: S0090-8258(18)30843.
    PubMed     Text format     Abstract available


  305. TEMPFER CB, Giger-Pabst U, Seebacher V, Petersen M, et al
    A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
    Gynecol Oncol. 2018 May 6. pii: S0090-8258(18)30851.
    PubMed     Text format     Abstract available


  306. KONSTANTINOPOULOS PA, Brady WE, Farley J, Armstrong A, et al
    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
    Gynecol Oncol. 2018 May 5. pii: S0090-8258(18)30850.
    PubMed     Text format     Abstract available


  307. NEBGEN DR, Hurteau J, Holman LL, Bradford A, et al
    Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Gynecol Oncol. 2018 May 4. pii: S0090-8258(18)30842.
    PubMed     Text format     Abstract available


  308. RICE LW
    Expanding the pipeline. The 2018 Society of Gynecologic Oncology presidential address. Sunday, March 25, 2018. By Laurel W. Rice, MD. 2017-2018 SGO president.
    Gynecol Oncol. 2018 May 2. pii: S0090-8258(18)30837.
    PubMed     Text format    


  309. TRIMBLE CL
    Towards identifying new therapeutic targets in cancers attributable to HPV.
    Gynecol Oncol. 2018;149:225-226.
    PubMed     Text format    


  310. HINTEN F, Molijn A, Eckhardt L, Massuger LFAG, et al
    Vulvar cancer: Two pathways with different localization and prognosis.
    Gynecol Oncol. 2018;149:310-317.
    PubMed     Text format     Abstract available


    April 2018
  311. NISKAKOSKI A, Pasanen A, Porkka N, Eldfors S, et al
    Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.
    Gynecol Oncol. 2018 Apr 28. pii: S0090-8258(18)30844.
    PubMed     Text format     Abstract available


  312. MAYADEV J, Klapheke A, Yashar C, Hsu IC, et al
    Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California.
    Gynecol Oncol. 2018 Apr 27. pii: S0090-8258(18)30841.
    PubMed     Text format     Abstract available


  313. NAGLE CM, Crosbie EJ, Brand A, Obermair A, et al
    The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer.
    Gynecol Oncol. 2018 Apr 26. pii: S0090-8258(18)30283.
    PubMed     Text format     Abstract available


  314. BROWN J, Naumann RW, Brady WE, Coleman RL, et al
    Clinical trial methodology in rare gynecologic tumor research: Strategies for success.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30285.
    PubMed     Text format     Abstract available


  315. WANG J, Garbutt C, Ma H, Gao P, et al
    Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30835.
    PubMed     Text format     Abstract available


  316. ROSSI A, Frechette L, Miller D, Miller E, et al
    Acceptability and feasibility of a Fitbit physical activity monitor for endometrial cancer survivors.
    Gynecol Oncol. 2018 Apr 21. pii: S0090-8258(18)30838.
    PubMed     Text format     Abstract available


  317. FERGUSON SE, Panzarella T, Lau S, Gien LT, et al
    Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer.
    Gynecol Oncol. 2018 Apr 19. pii: S0090-8258(18)30836.
    PubMed     Text format     Abstract available


  318. EL-ZEIN M, Bouten S, Louvanto K, Gilbert L, et al
    Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
    Gynecol Oncol. 2018 Apr 17. pii: S0090-8258(18)30274.
    PubMed     Text format     Abstract available


  319. MATODA M, Takeshima N, Michimae H, Iwata T, et al
    Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30286.
    PubMed     Text format     Abstract available


  320. BERGSTROM JE, Scott ME, Alimi Y, Yen TT, et al
    Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30273.
    PubMed     Text format     Abstract available


  321. CHAPEL DB, Yamada SD, Cowan M, Lastra RR, et al
    Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30282.
    PubMed     Text format     Abstract available


  322. JIANG F, Wan XR, Xu T, Feng FZ, et al
    Evaluation and suggestions for improving the FIGO 2000 staging criteria for gestational trophoblastic neoplasia: A ten-year review of 1420 patients.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30271.
    PubMed     Text format     Abstract available


  323. UYAR D, Neary J, Monroe A, Nugent M, et al
    Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30239.
    PubMed     Text format     Abstract available


  324. LIU J, Nicum S, Reichardt P, Croitoru K, et al
    Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
    Gynecol Oncol. 2018 Apr 4. pii: S0090-8258(18)30238.
    PubMed     Text format     Abstract available


  325. ARMBRUSTER SD, Sun CC, Westin SN, Bodurka DC, et al
    Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration.
    Gynecol Oncol. 2018 Apr 2. pii: S0090-8258(18)30234.
    PubMed     Text format     Abstract available


  326. DOCKERY LE, Motwani A, Ding K, Doescher M, et al
    Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.
    Gynecol Oncol. 2018;149:89-92.
    PubMed     Text format     Abstract available


  327. MANRRIQUEZ E, Chapman JS, Mak J, Blanco AM, et al
    Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    Gynecol Oncol. 2018;149:84-88.
    PubMed     Text format     Abstract available


  328. DOLL KM
    Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications.
    Gynecol Oncol. 2018;149:78-83.
    PubMed     Text format     Abstract available


  329. TEMKIN SM, Rimel BJ, Bruegl AS, Gunderson CC, et al
    A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review.
    Gynecol Oncol. 2018;149:70-77.
    PubMed     Text format     Abstract available


  330. HAGOPIAN GS, Lieber M, Dottino PR, Margaret Kemeny M, et al
    The impact of nativity on cervical cancer survival in the public hospital system of Queens, New York.
    Gynecol Oncol. 2018;149:63-69.
    PubMed     Text format     Abstract available


  331. RAMEY SJ, Asher D, Kwon D, Ahmed AA, et al
    Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact.
    Gynecol Oncol. 2018;149:53-62.
    PubMed     Text format     Abstract available


  332. DILLEY S, Erickson BK, Phillips CE, Kennemer CR, et al
    Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
    Gynecol Oncol. 2018;149:49-52.
    PubMed     Text format     Abstract available


  333. COWAN RA, Tseng J, Ali N, Dearie H, et al
    Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
    Gynecol Oncol. 2018;149:43-48.
    PubMed     Text format     Abstract available


  334. RAUH-HAIN JA, Melamed A, Schaps D, Bregar AJ, et al
    Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies.
    Gynecol Oncol. 2018;149:4-11.
    PubMed     Text format     Abstract available


  335. LEE J, Gerber D, Aphinyanaphongs Y, Curtin JP, et al
    Laparoscopy decreases the disparity in postoperative complications between black and white women after hysterectomy for endometrial cancer.
    Gynecol Oncol. 2018;149:22-27.
    PubMed     Text format     Abstract available


  336. DUBIL EA, Tian C, Wang G, Tarney CM, et al
    Racial disparities in molecular subtypes of endometrial cancer.
    Gynecol Oncol. 2018;149:106-116.
    PubMed     Text format     Abstract available


  337. STAPLES JN, Wong MS, Rimel BJ
    An educational intervention to improve human papilloma virus (HPV) and cervical cancer knowledge among African American college students.
    Gynecol Oncol. 2018;149:101-105.
    PubMed     Text format     Abstract available


  338. DEL CARMEN MG, Rice LW
    Towards the elimination of health care disparities in gynecologic oncology: Call to action.
    Gynecol Oncol. 2018;149:1-3.
    PubMed     Text format    


  339. MAO X, Qin X, Li L, Zhou J, et al
    A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma.
    Gynecol Oncol. 2018;149:181-187.
    PubMed     Text format     Abstract available


  340. MOORE KN, Mirza MR, Matulonis UA
    The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Gynecol Oncol. 2018;149:214-220.
    PubMed     Text format     Abstract available


    March 2018
  341. BONHOF CS, Mols F, Vos MC, Pijnenborg JMA, et al
    Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30232.
    PubMed     Text format     Abstract available


  342. WU H, Zhang J
    Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30237.
    PubMed     Text format     Abstract available


  343. CUNNINGHAM-ERVES J, Forbes L, Ivankova N, Mayo-Gamble T, et al
    Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication.
    Gynecol Oncol. 2018 Mar 24. pii: S0090-8258(18)30219.
    PubMed     Text format     Abstract available


  344. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer.
    Gynecol Oncol. 2018 Mar 21. pii: S0090-8258(18)30231.
    PubMed     Text format    


  345. LONG J, Zhu JY, Liu YB, Fu K, et al
    Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30176.
    PubMed     Text format     Abstract available


  346. CHEN L, Luan S, Xia B, Liu Y, et al
    Integrated analysis of HPV-mediated immune alterations in cervical cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30070.
    PubMed     Text format     Abstract available


  347. KIM J, Kim S, Lee HS, Yang W, et al
    Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30132.
    PubMed     Text format     Abstract available


  348. MCDONALD JF
    Back to the future - The integration of big data with machine learning is re-establishing the importance of predictive correlations in ovarian cancer diagnostics and therapeutics.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30233.
    PubMed     Text format    


  349. HAN C, Bellone S, Siegel ER, Altwerger G, et al
    A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30230.
    PubMed     Text format     Abstract available


  350. WILSON AJ, Stubbs M, Liu P, Ruggeri B, et al
    The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30229.
    PubMed     Text format     Abstract available


  351. AGRAWAL S, Chen L, Tergas AI, Hou JY, et al
    Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30220.
    PubMed     Text format     Abstract available


  352. VENIGALLA S, Chowdhry AK, Shalowitz DI
    Survival implications of staging lymphadenectomy for non-endometrioid endometrial cancers.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30218.
    PubMed     Text format     Abstract available


  353. IDAHL A, Hermansson A, Lalos A
    Social support and ovarian cancer incidence - A Swedish prospective population-based study.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30214.
    PubMed     Text format     Abstract available


  354. CARLTON AL, Illendula A, Gao Y, Llaneza DC, et al
    Small molecule inhibition of the CBFbeta/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.
    Gynecol Oncol. 2018 Mar 15. pii: S0090-8258(18)30174.
    PubMed     Text format     Abstract available


  355. ESKANDER RN, Kauderer J, Tewari KS, Mannel RS, et al
    Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30216.
    PubMed     Text format     Abstract available


  356. TORTORELLA L, Langstraat CL, Weaver AL, McGree ME, et al
    Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30141.
    PubMed     Text format     Abstract available


  357. UCCELLA S, Mele MC, Quagliozzi L, Rinninella E, et al
    Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30215.
    PubMed     Text format     Abstract available


  358. BRUCE SF, Carr DN, Burton ER, Sorosky JI, et al
    Implementation of an abdominal closure bundle to reduce surgical site infection in patients on a gynecologic oncology service undergoing exploratory laparotomy.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30217.
    PubMed     Text format     Abstract available


  359. KO EM, Havrilesky LJ, Alvarez RD, Zivanovic O, et al
    Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP).
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30130.
    PubMed     Text format     Abstract available


  360. RAMZAN AA, Fischer S, Buss MK, Urban RR, et al
    Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II - Balancing safety & accessibility.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30127.
    PubMed     Text format     Abstract available


  361. QU XM, Velker VM, Leung E, Kwon JS, et al
    The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30172.
    PubMed     Text format     Abstract available


  362. PRZYBYL J, Kidzinski L, Hastie T, Debiec-Rychter M, et al
    Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30177.
    PubMed     Text format     Abstract available


  363. MATSUO K, Yabuno A, Hom MS, Shida M, et al
    Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30131.
    PubMed     Text format     Abstract available


  364. STEWART LE, Beck TL, Giannakopoulos NV, Rendi MH, et al
    Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: A multicenter review.
    Gynecol Oncol. 2018 Mar 11. pii: S0090-8258(18)30180.
    PubMed     Text format     Abstract available


  365. YI L, Zhang H, Zou J, Luo P, et al
    Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30175.
    PubMed     Text format     Abstract available


  366. GOSTNER JM, Obermayr E, Braicu IE, Concin N, et al
    Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30139.
    PubMed     Text format     Abstract available


  367. VON GRUENIGEN VE, Karlan BY
    Sexual harassment in the work place: Its impact on gynecologic oncology and women's health.
    Gynecol Oncol. 2018 Mar 8. pii: S0090-8258(18)30137.
    PubMed     Text format     Abstract available


  368. SCHORGE JO, Bregar AJ, Durfee J, Berkowitz RS, et al
    Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer.
    Gynecol Oncol. 2018 Mar 7. pii: S0090-8258(18)30142.
    PubMed     Text format     Abstract available


  369. SCHUURMAN MS, Kruitwagen RFPM, Portielje JEA, Roes EM, et al
    Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30136.
    PubMed     Text format     Abstract available


  370. LIAO CI, Chow S, Chen LM, Kapp DS, et al
    Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30069.
    PubMed     Text format     Abstract available


  371. KANAO H, Aoki Y, Hisa T, Takeshima N, et al
    Laparoscopic laterally extended endopelvic resection (LEER) for cervical carcinoma recurring at the pelvic sidewall after concurrent chemoradiotherapy: Our experience in three cases.
    Gynecol Oncol. 2018 Mar 3. pii: S0090-8258(18)30112.
    PubMed     Text format     Abstract available


  372. BUSKWOFIE A, Huang Y, Tergas AI, Hou JY, et al
    Impact of hospital volume on racial disparities and outcomes for endometrial cancer.
    Gynecol Oncol. 2018 Mar 2. pii: S0090-8258(18)30138.
    PubMed     Text format     Abstract available


  373. HARKENRIDER MM, Altoos B, Small W Jr.
    Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
    Gynecol Oncol. 2018;148:437-438.
    PubMed     Text format    


  374. MINION LE, Tewari KS
    Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Gynecol Oncol. 2018;148:609-621.
    PubMed     Text format     Abstract available


  375. POWELL CB, Alabaster A, Stoller N, Armstrong MA, et al
    Bone loss in women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2018;148:535-539.
    PubMed     Text format     Abstract available


  376. STECKLEIN SR, Frumovitz M, Klopp AH, Gunther JR, et al
    Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy.
    Gynecol Oncol. 2018;148:474-479.
    PubMed     Text format     Abstract available


  377. FILIPPOV-LEVY N, Cohen-Schussheim H, Trope CG, Hetland Falkenthal TE, et al
    Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Gynecol Oncol. 2018;148:559-566.
    PubMed     Text format     Abstract available


  378. TE GROOTENHUIS NC, Pouwer AW, de Bock GH, Hollema H, et al
    Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review.
    Gynecol Oncol. 2018;148:622-631.
    PubMed     Text format     Abstract available


    February 2018
  379. XIAO X, Dong D, He W, Song L, et al
    Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30128.
    PubMed     Text format     Abstract available


  380. WRIGHT JD, Havrilesky LJ, Cohn DE, Huang Y, et al
    Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30129.
    PubMed     Text format     Abstract available


  381. WEAVER DT, Raphel TJ, Melamed A, Rauh-Hain JA, et al
    Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30126.
    PubMed     Text format     Abstract available


  382. HUVILA J, Laajala TD, Edqvist PH, Mardinoglu A, et al
    Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30135.
    PubMed     Text format     Abstract available


  383. BARRINGTON DA, Champion ML, Boitano TKL, Walters-Haygood CL, et al
    Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30133.
    PubMed     Text format     Abstract available


  384. JAREID M, Thalabard JC, Aarflot M, Bovelstad HM, et al
    Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30125.
    PubMed     Text format     Abstract available


  385. PAREJA R, Echeverri L, Rendon G, Munsell M, et al
    Radical parametrectomy after 'cut-through' hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30134.
    PubMed     Text format     Abstract available


  386. LHEUREUX S, McCourt C, Rimel BJ, Duska L, et al
    Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.
    Gynecol Oncol. 2018 Feb 21. pii: S0090-8258(18)30124.
    PubMed     Text format     Abstract available


  387. LEFKOWITS C, Buss MK, Ramzan AA, Fischer S, et al
    Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review.
    Gynecol Oncol. 2018 Feb 20. pii: S0090-8258(18)30066.
    PubMed     Text format     Abstract available


  388. KELLENBERGER LD, Petrik J
    Hyperglycemia promotes insulin-independent ovarian tumor growth.
    Gynecol Oncol. 2018 Feb 17. pii: S0090-8258(18)30122.
    PubMed     Text format     Abstract available


  389. OZA A, Kaye S, Van Tornout J, Sessa C, et al
    Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Gynecol Oncol. 2018 Feb 14. pii: S0090-8258(18)30058.
    PubMed     Text format     Abstract available


  390. LI Y, Wu T, Wang Y, Yang L, et al
    gamma-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30062.
    PubMed     Text format     Abstract available


  391. CRANE EK, Brown J
    Early stage mucinous ovarian cancer: A review.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30074.
    PubMed     Text format     Abstract available


  392. DESAI P, Wallace R, Anderson ML, Howard BV, et al
    An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
    Gynecol Oncol. 2018 Feb 5. pii: S0090-8258(18)30038.
    PubMed     Text format     Abstract available


  393. HACKER KE, Reynolds RK, Uppal S
    Ongoing strategies and updates on pain management in gynecologic oncology patients.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30073.
    PubMed     Text format     Abstract available


  394. SWANSON CL, Kumar A, Maharaj JM, Kemppainen JL, et al
    Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30072.
    PubMed     Text format     Abstract available


  395. MILLER KR, Patel JN, Zhang Q, Norris EJ, et al
    HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30061.
    PubMed     Text format     Abstract available


  396. THARAVICHITKUL E, Chakrabandhu S, Klunklin P, Onchan W, et al
    Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30047.
    PubMed     Text format     Abstract available


  397. STROHL AE, Lurain JR
    Nonmetastatic Excised Gestational Choriocarcinoma: To Treat or Not to Treat.
    Gynecol Oncol. 2018;148:237-238.
    PubMed     Text format    


  398. NAUMANN RW, Brown J
    Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Gynecol Oncol. 2018 Feb 1. pii: S0090-8258(18)30068.
    PubMed     Text format     Abstract available


  399. KIM SI, Lee S, Jeong CW, Kim HS, et al
    Robot-assisted anterior pelvic exenteration in vulvovaginal malignant melanoma.
    Gynecol Oncol. 2018;148:430-431.
    PubMed     Text format     Abstract available


  400. FU S, Lairson DR, Chan W, Wu CF, et al
    Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas.
    Gynecol Oncol. 2018;148:342-348.
    PubMed     Text format     Abstract available


  401. KANG WD, Ju UC, Kim SM
    Is human papillomavirus genotype important in predicting disease progression in women with biopsy-proven negative or CIN1 of atypical squamous cell of undetermined significance (ASC-US) cytology?
    Gynecol Oncol. 2018;148:305-310.
    PubMed     Text format     Abstract available


    January 2018
  402. ARMBRUSTER SD, Song J, Gatus L, Lu KH, et al
    Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30067.
    PubMed     Text format     Abstract available


  403. DEWDNEY SB, Dancisak AC, Lachance JA, Grendys EC Jr, et al
    Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30060.
    PubMed     Text format     Abstract available


  404. GRIMM C, Polterauer S, Helmy-Bader S, Zikan M, et al
    A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30044.
    PubMed     Text format     Abstract available


  405. GUNDERSON CC, Matulonis U, Moore KN
    Management of the toxicities of common targeted therapeutics for gynecologic cancers.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30042.
    PubMed     Text format     Abstract available


  406. KESSOUS R, Octeau D, Klein K, Tonin PN, et al
    Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30055.
    PubMed     Text format     Abstract available


  407. HENRY CE, Llamosas E, Daniels B, Coopes A, et al
    ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30064.
    PubMed     Text format     Abstract available


  408. NITECKI R, Diver EJ, Kamdar MM, Boruta DM 2nd, et al
    Patterns of palliative care referral in ovarian cancer: A single institution 5year retrospective analysis.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30056.
    PubMed     Text format     Abstract available


  409. ZHANG HR, Lai SY, Huang LJ, Zhang ZF, et al
    Myosin 1b promotes cell proliferation, migration, and invasion in cervical cancer.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30065.
    PubMed     Text format     Abstract available


  410. PENNINGTON KP, McTiernan A
    The role of physical activity in breast and gynecologic cancer survivorship.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30059.
    PubMed     Text format     Abstract available


  411. KATO K, Okamoto S, Ota E, Takeshima N, et al
    Secondary debulking surgery for para-aortic nodal recurrence in endometrial cancer requiring circumferential resection of the inferior vena cava.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30063.
    PubMed     Text format    


  412. SAMIMI G, Trabert B, Duggan MA, Robinson JL, et al
    Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    Gynecol Oncol. 2018 Jan 25. pii: S0090-8258(18)30048.
    PubMed     Text format     Abstract available


  413. KRISHNAN V, Schaar B, Tallapragada S, Dorigo O, et al
    Tumor associated macrophages in gynecologic cancers.
    Gynecol Oncol. 2018 Jan 22. pii: S0090-8258(18)30046.
    PubMed     Text format     Abstract available


  414. DOSTALEK L, Zikan M, Fischerova D, Kocian R, et al
    SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm.
    Gynecol Oncol. 2018 Jan 21. pii: S0090-8258(18)30001.
    PubMed     Text format     Abstract available


  415. BARROILHET L, Matulonis U
    The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Gynecol Oncol. 2018 Jan 20. pii: S0090-8258(18)30040.
    PubMed     Text format     Abstract available


  416. GRAY HJ, Bell-McGuinn K, Fleming GF, Cristea M, et al
    Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620.
    PubMed     Text format     Abstract available


  417. BERGSTROM J, Aloisi A, Armbruster S, Yen TT, et al
    Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.
    Gynecol Oncol. 2018 Jan 12. pii: S0090-8258(18)30002.
    PubMed     Text format     Abstract available


  418. SHALOWITZ DI, Cohn DE
    Cancer care delivery research in gynecologic oncology.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31618.
    PubMed     Text format    


  419. TRABERT B, Aarestrup J, Ulrich LG, Wentzensen N, et al
    Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31622.
    PubMed     Text format     Abstract available


  420. PARK SH, Cheon H, Chong GO, Jeong SY, et al
    Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(18)30037.
    PubMed     Text format     Abstract available


  421. HAGEMANN AR, McCourt CK, Varaday SS, Moore KN, et al
    Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31608.
    PubMed     Text format     Abstract available


  422. SAED GM, Fletcher NM, Diamond MP, Morris RT, et al
    Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31606.
    PubMed     Text format     Abstract available


  423. BACORRO W, Dumas I, Escande A, Gouy S, et al
    Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer.
    Gynecol Oncol. 2018 Jan 8. pii: S0090-8258(17)31621.
    PubMed     Text format     Abstract available


  424. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
    Gynecol Oncol. 2018 Jan 5. pii: S0090-8258(17)31619.
    PubMed     Text format    


  425. MUKERJI B, Baptiste C, Chen L, Tergas AI, et al
    Racial disparities in young women with endometrial cancer.
    Gynecol Oncol. 2018 Jan 4. pii: S0090-8258(17)31623.
    PubMed     Text format     Abstract available


  426. DONG L, Wang MZ, Zhao XL, Feng RM, et al
    Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
    Gynecol Oncol. 2018;148:103-110.
    PubMed     Text format     Abstract available


  427. GOROSTIDI M, Villalain C, Ruiz R, Jaunarena I, et al
    Technique for precaval and laterocaval nodes excision at extraperitoneal paraaortic lymphadenectomy.
    Gynecol Oncol. 2018;148:233-234.
    PubMed     Text format     Abstract available


  428. SATMARY W, Holschneider CH, Brunette LL, Natarajan S, et al
    Vulvar intraepithelial neoplasia: Risk factors for recurrence.
    Gynecol Oncol. 2018;148:126-131.
    PubMed     Text format     Abstract available


    December 2017
  429. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
    Gynecol Oncol. 2017 Dec 28. pii: S0090-8258(17)31617.
    PubMed     Text format     Abstract available


  430. SOISSON S, Ganz PA, Gaffney D, Rowe K, et al
    Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
    Gynecol Oncol. 2017 Dec 27. pii: S0090-8258(17)31616.
    PubMed     Text format     Abstract available


  431. XIANG L, Jiang W, Ye S, He T, et al
    ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Gynecol Oncol. 2017 Dec 23. pii: S0090-8258(17)31614.
    PubMed     Text format     Abstract available


  432. SUD S, Holmes J, Eblan M, Chen R, et al
    Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis.
    Gynecol Oncol. 2017 Dec 21. pii: S0090-8258(17)31607.
    PubMed     Text format     Abstract available


  433. MONTEALEGRE JR, Peckham-Gregory EC, Marquez-Do D, Dillon L, et al
    Racial/ethnic differences in HPV 16/18 genotypes and integration status among women with a history of cytological abnormalities.
    Gynecol Oncol. 2017 Dec 21. pii: S0090-8258(17)31597.
    PubMed     Text format     Abstract available


  434. GEPPERT B, Lonnerfors C, Bollino M, Persson J, et al
    Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications.
    Gynecol Oncol. 2017 Dec 20. pii: S0090-8258(17)31602.
    PubMed     Text format     Abstract available


  435. TRAN AQ, Erim DO, Sullivan SA, Cole AL, et al
    Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31598.
    PubMed     Text format     Abstract available


  436. FORNALIK H, Fornalik N
    Robotic hysterectomy and pelvic lymphadenectomy without Trendelenburg position (BMI 36).
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31549.
    PubMed     Text format    


  437. LEE J, Lin JB, Chang CL, Sun FJ, et al
    Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
    Gynecol Oncol. 2017 Dec 18. pii: S0090-8258(17)31550.
    PubMed     Text format     Abstract available


  438. MIAO M, Deng G, Luo S, Zhou J, et al
    A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31596.
    PubMed     Text format     Abstract available


  439. MATSUO K, Ross MS, Im DD, Klobocista MM, et al
    Significance of venous thromboembolism in women with uterine carcinosarcoma.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31546.
    PubMed     Text format     Abstract available


  440. BRAGA A, Campos V, Filho JR, Lin LH, et al
    Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31554.
    PubMed     Text format     Abstract available


  441. CASTLE PE, Pierz A, Stoler MH
    A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31548.
    PubMed     Text format     Abstract available


  442. DILLEY S, Miller K, Huh W
    HPV vaccination.
    Gynecol Oncol. 2017 Dec 12. pii: S0090-8258(17)31547.
    PubMed     Text format    


  443. BERNARDS SS, Pennington KP, Harrell MI, Agnew KJ, et al
    Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31551.
    PubMed     Text format     Abstract available


  444. KIM SI, Lee JW, Lee M, Kim HS, et al
    Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31552.
    PubMed     Text format     Abstract available


  445. COYLE C, Short D, Jackson L, Sebire NJ, et al
    What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31555.
    PubMed     Text format     Abstract available


  446. BIZZARRI N, Ghirardi V, Kucukmetin A
    Indocyanine green-assisted parametrial dissection during type C1 radical hysterectomy after sentinel lymph node biopsy in early stage cervical cancer.
    Gynecol Oncol. 2017 Dec 6. pii: S0090-8258(17)31496.
    PubMed     Text format     Abstract available


  447. WALLACE S, Hanson KT, Dowdy SC, Habermann EB, et al
    Impact of surgical approach and patient factors on Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey scoring in gynecologic surgery.
    Gynecol Oncol. 2017 Dec 5. pii: S0090-8258(17)31525.
    PubMed     Text format     Abstract available


  448. SMITH D, Stewart CJR, Clarke EM, Lose F, et al
    ER and PR expression and survival after endometrial cancer.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31537.
    PubMed     Text format     Abstract available


  449. WORLEY MJ JR, Elias KM, Horowitz NS, Quade BJ, et al
    Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31539.
    PubMed     Text format     Abstract available


  450. ANNUNZIATA CM, Kohn EC
    Clinical trials in gynecologic oncology: Past, present, and future.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31536.
    PubMed     Text format     Abstract available


  451. URBAN RR, He H, Alfonso R, Hardesty MM, et al
    The end of life costs for Medicare patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31533.
    PubMed     Text format     Abstract available


  452. WEN KC, Sung PL, Chou YT, Pan CM, et al
    The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma.
    Gynecol Oncol. 2017 Dec 2. pii: S0090-8258(17)31543.
    PubMed     Text format     Abstract available


  453. AVIKI EM, Abu-Rustum NR
    A call to standardize our approach to fertility-sparing surgery in patients with gynecologic cancers.
    Gynecol Oncol. 2017;147:491-492.
    PubMed     Text format    


  454. BITLER BG, Watson ZL, Wheeler LJ, Behbakht K, et al
    PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    Gynecol Oncol. 2017;147:695-704.
    PubMed     Text format     Abstract available


  455. NOMURA H, Nagashima M, Aoki Y, Takeshima N, et al
    Resection of the inferior pubic ramus to completely remove locally advance adenoid cystic carcinoma of Bartholin's gland.
    Gynecol Oncol. 2017;147:723-724.
    PubMed     Text format     Abstract available


  456. PEI X, Xiang L, Ye S, He T, et al
    Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2017;147:589-596.
    PubMed     Text format     Abstract available


  457. KUMAR A, Hurtt CC, Cliby WA, Martin JR, et al
    Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
    Gynecol Oncol. 2017;147:514-520.
    PubMed     Text format     Abstract available


  458. REISER E, Aust S, Seebacher V, Reinthaller A, et al
    Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Gynecol Oncol. 2017;147:690-694.
    PubMed     Text format     Abstract available


  459. CYBULSKA P, Goss C, Tew WP, Parameswaran R, et al
    Corrigendum to "Indications for and complications of transfusion and the management of gynecologic malignancies" [Gynecol. Oncol. 146 (2017) 416-426].
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31540.
    PubMed     Text format    


  460. MAHANTSHETTY U, Teni T, Naga P, Hotwani C, et al
    Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study.
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31544.
    PubMed     Text format     Abstract available


  461. LI J, Li S, Yu H, Wang J, et al
    The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31541.
    PubMed     Text format     Abstract available


    November 2017
  462. HAMILTON CA, Miller A, Casablanca Y, Horowitz NS, et al
    Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Gynecol Oncol. 2017 Nov 28. pii: S0090-8258(17)31528.
    PubMed     Text format     Abstract available


  463. ZHU J, Chen Z, Yong L
    Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
    Gynecol Oncol. 2017 Nov 27. pii: S0090-8258(17)31538.
    PubMed     Text format     Abstract available


  464. KITSON SJ, Lindsay J, Sivalingam VN, Lunt M, et al
    The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study.
    Gynecol Oncol. 2017 Nov 24. pii: S0090-8258(17)31529.
    PubMed     Text format     Abstract available


  465. MURALI R, Grisham RN, Soslow RA
    The roles of pathology in targeted therapy of women with gynecologic cancers.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530.
    PubMed     Text format     Abstract available


  466. MOSS HA, Havrilesky LJ
    The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31507.
    PubMed     Text format     Abstract available


  467. GULERIA S, Jensen A, Kjaer SK
    Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31534.
    PubMed     Text format     Abstract available


  468. HOROWITZ NS, Larry Maxwell G, Miller A, Hamilton CA, et al
    Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
    Gynecol Oncol. 2017 Nov 22. pii: S0090-8258(17)31371.
    PubMed     Text format     Abstract available


  469. LEE YJ, Chung YS, Lee JY, Nam EJ, et al
    Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Nov 21. pii: S0090-8258(17)31532.
    PubMed     Text format     Abstract available


  470. TOZZI R, Casarin J, Garruto-Campanile R, Majd HS, et al
    Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Gynecol Oncol. 2017 Nov 20. pii: S0090-8258(17)31527.
    PubMed     Text format     Abstract available


  471. HEINZELMANN-SCHWARZ V, Knipprath Meszaros A, Stadlmann S, Jacob F, et al
    Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Gynecol Oncol. 2017 Nov 17. pii: S0090-8258(17)31458.
    PubMed     Text format     Abstract available


  472. CHAMPER M, Huang Y, Hou JY, Tergas AI, et al
    Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31504.
    PubMed     Text format     Abstract available


  473. CHOLLI P, Bradford L, Manga S, Nulah K, et al
    Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31497.
    PubMed     Text format     Abstract available


  474. CHONG GO, Lee YH, Han HS, Lee HJ, et al
    Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31498.
    PubMed     Text format     Abstract available


  475. SHISLER R, Sinnott JA, Wang V, Hebert C, et al
    Life after endometrial cancer: A systematic review of patient-reported outcomes.
    Gynecol Oncol. 2017 Nov 14. pii: S0090-8258(17)31503.
    PubMed     Text format     Abstract available


  476. LIE AK, Trope A, Skare GB, Bjorge T, et al
    HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia.
    Gynecol Oncol. 2017 Nov 11. pii: S0090-8258(17)31453.
    PubMed     Text format     Abstract available


  477. TAKIUCHI T, Blake EA, Matsuo K, Sood AK, et al
    Aspirin use and endometrial cancer risk and survival.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31448.
    PubMed     Text format     Abstract available


  478. SHAH JS, Gard GB, Yang J, Maidens J, et al
    Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31500.
    PubMed     Text format     Abstract available


  479. COSGROVE CM, Tritchler DL, Cohn DE, Mutch DG, et al
    An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31459.
    PubMed     Text format     Abstract available


  480. TIMMERMANS M, Schuurman MS, Ho VKY, Massuger LF, et al
    Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31505.
    PubMed     Text format     Abstract available


  481. MERT I, Kumar A, Sheedy SP, Weaver AL, et al
    Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31446.
    PubMed     Text format     Abstract available


  482. NIETO K, Adams W, Pham N, Block AM, et al
    Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31506.
    PubMed     Text format     Abstract available


  483. HOPPENOT C, Eckert MA, Tienda SM, Lengyel E, et al
    Who are the long-term survivors of high grade serous ovarian cancer?
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454.
    PubMed     Text format     Abstract available


  484. HINCHCLIFF E, Melamed A, Bregar A, Diver E, et al
    Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31460.
    PubMed     Text format     Abstract available


  485. SPAANS VM, Nyoman Bayu Mahendra I, Purwoto G, Trietsch MD, et al
    The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
    Gynecol Oncol. 2017 Nov 4. pii: S0090-8258(17)31369.
    PubMed     Text format     Abstract available


  486. ISHIKAWA M, Kasamatsu T, Tsuda H, Fukunaga M, et al
    Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study.
    Gynecol Oncol. 2017 Nov 4. pii: S0090-8258(17)31449.
    PubMed     Text format     Abstract available


  487. CHAN JK, Kapp DS
    Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy.
    Gynecol Oncol. 2017;147:237-239.
    PubMed     Text format    


  488. ALTMAN AD, McGee J, May T, Lane K, et al
    Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
    Gynecol Oncol. 2017;147:257-261.
    PubMed     Text format     Abstract available


    October 2017
  489. FONNES T, Berg HF, Bredholt T, Edqvist PD, et al
    Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
    Gynecol Oncol. 2017 Oct 30. pii: S0090-8258(17)31447.
    PubMed     Text format     Abstract available


  490. MAESTA I, Nitecki R, Horowitz NS, Goldstein DP, et al
    Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Gynecol Oncol. 2017 Oct 29. pii: S0090-8258(17)31450.
    PubMed     Text format     Abstract available


  491. NING MS, Ahobila V, Jhingran A, Stecklein SR, et al
    Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.
    Gynecol Oncol. 2017 Oct 28. pii: S0090-8258(17)31420.
    PubMed     Text format     Abstract available


  492. LEE JH, Lee SW, Kim JR, Kim YS, et al
    Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01.
    Gynecol Oncol. 2017 Oct 27. pii: S0090-8258(17)31360.
    PubMed     Text format     Abstract available


  493. CHENG H, Peng J, Yang Z, Zhang G, et al
    Prognostic significance of lymphadenectomyin malignant ovarian sex cord stromal tumor: A retrospective cohort study and meta-analysis.
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31444.
    PubMed     Text format     Abstract available


  494. RONCOLATO FT, Berton-Rigaud D, O'Connell R, Lanceley A, et al
    Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422.
    PubMed     Text format     Abstract available


  495. LIN DI, Chudnovsky Y, Duggan B, Zajchowski D, et al
    Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Gynecol Oncol. 2017 Oct 25. pii: S0090-8258(17)31355.
    PubMed     Text format     Abstract available


  496. SHALOWITZ DI, Nivasch E, Burger RA, Schapira MM, et al
    Are patients willing to travel for better ovarian cancer care?
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31421.
    PubMed     Text format     Abstract available


  497. YI Y, Tsai SH, Cheng JC, Wang EY, et al
    APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31419.
    PubMed     Text format     Abstract available


  498. LAAN JJ, van Lonkhuijzen LRCW, van Os RM, Tytgat KM, et al
    Socioeconomic status as an independent risk factor for severe late bowel toxicity after primary radiotherapy for cervical cancer.
    Gynecol Oncol. 2017 Oct 23. pii: S0090-8258(17)31416.
    PubMed     Text format     Abstract available


  499. MATSUO K, Ross MS, Yunokawa M, Johnson MS, et al
    Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
    Gynecol Oncol. 2017 Oct 19. pii: S0090-8258(17)31368.
    PubMed     Text format     Abstract available


  500. TANNER E, Puechl A, Levinson K, Havrilesky LJ, et al
    Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer.
    Gynecol Oncol. 2017 Oct 19. pii: S0090-8258(17)31423.
    PubMed     Text format     Abstract available


  501. YAMAMOTO K, Nagao S, Suzuki K, Kogiku A, et al
    Pelvic fractures after definitive and postoperative radiotherapy for cervical cancer: A retrospective analysis of risk factors.
    Gynecol Oncol. 2017 Oct 18. pii: S0090-8258(17)31359.
    PubMed     Text format     Abstract available


  502. ARIMA R, Hautakoski A, Marttila M, Arffman M, et al
    Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31417.
    PubMed     Text format     Abstract available


  503. JONES MR, Kamara D, Karlan BY, Pharoah PDP, et al
    Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31361.
    PubMed     Text format     Abstract available


  504. CHEN BJ, Byrne FL, Takenaka K, Modesitt SC, et al
    Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer.
    Gynecol Oncol. 2017 Oct 16. pii: S0090-8258(17)31367.
    PubMed     Text format     Abstract available


  505. SCHULTZ KAP, Harris AK, Finch M, Dehner LP, et al
    DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31358.
    PubMed     Text format     Abstract available


  506. DOCKERY LE, Tew WP, Ding K, Moore KN, et al
    Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31364.
    PubMed     Text format     Abstract available


  507. POZZAR RA, Berry DL
    Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care.
    Gynecol Oncol. 2017 Oct 10. pii: S0090-8258(17)31365.
    PubMed     Text format     Abstract available


  508. DE LIMA MAP, Neto PJN, Lima LPM, Goncalves Junior J, et al
    Association between Epstein-Barr virus (EBV) and cervical carcinoma: A meta-analysis.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31366.
    PubMed     Text format     Abstract available


  509. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31370.
    PubMed     Text format     Abstract available


  510. XIA Z, Cochrane DR, Anglesio MS, Wang YK, et al
    LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31356.
    PubMed     Text format     Abstract available


  511. BUDA A, Di Martino G, Restaino S, De Ponti E, et al
    The impact on survival of two different staging strategies in apparent early stage endometrial cancer comparing sentinel lymph nodes mapping algorithm and selective lymphadenectomy: An Italian retrospective analysis of two reference centers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31357.
    PubMed     Text format     Abstract available


  512. PEPIN K, Bregar A, Davis M, Melamed A, et al
    Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
    Gynecol Oncol. 2017 Oct 4. pii: S0090-8258(17)31352.
    PubMed     Text format     Abstract available


  513. MATSUO K, Machida H, Frimer M, Marcus JZ, et al
    Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
    Gynecol Oncol. 2017 Oct 3. pii: S0090-8258(17)31351.
    PubMed     Text format     Abstract available


  514. SINGH S, Swarer K, Resnick K
    Longer operative time is associated with increased post-operative complications in patients undergoing minimally-invasive surgery for endometrial cancer.
    Gynecol Oncol. 2017 Oct 2. pii: S0090-8258(17)31348.
    PubMed     Text format     Abstract available


  515. HENSLEY ML
    Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there".
    Gynecol Oncol. 2017;147:1-2.
    PubMed     Text format    


  516. POLTERAUER S, Schwameis R, Grimm C, Macuks R, et al
    Prognostic value of lymph node ratio and number of positive inguinal nodes in patients with vulvar cancer.
    Gynecol Oncol. 2017;147:92-97.
    PubMed     Text format     Abstract available


    September 2017
  517. DEVOR EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, et al
    Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 29. pii: S0090-8258(17)31349.
    PubMed     Text format     Abstract available


  518. DUCIE JA, Eriksson AGZ, Ali N, McGree ME, et al
    Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31354.
    PubMed     Text format     Abstract available


  519. PHILP L, Covens A, Vicus D, Kupets R, et al
    Feasibility and safety of same-day discharge after laparoscopic radical hysterectomy for cervix cancer.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31350.
    PubMed     Text format     Abstract available


  520. QIU C, Lu N, Wang X, Zhang Q, et al
    Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31353.
    PubMed     Text format     Abstract available


  521. TORRES D, Kumar A, Wallace SK, Bakkum-Gamez JN, et al
    Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 27. pii: S0090-8258(17)31345.
    PubMed     Text format     Abstract available


  522. COSGROVE CM, Cohn DE, Goodfellow PJ
    Primum non nocere: Are we ready for POLE testing in endometrial cancer?
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31339.
    PubMed     Text format    


  523. CYBULSKA P, Schiavone MB, Sawyer B, Gardner GJ, et al
    Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer.
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31302.
    PubMed     Text format     Abstract available


  524. NELSON G, Dowdy SC, Lasala J, Mena G, et al
    Enhanced recovery after surgery (ERAS(R)) in gynecologic oncology - Practical considerations for program development.
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31347.
    PubMed     Text format    


  525. MAKKONEN P, Heinavaara S, Sarkeala T, Anttila A, et al
    Impact of organized and opportunistic Pap testing on the risk of cervical cancer in young women - A case-control study from Finland.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31335.
    PubMed     Text format     Abstract available


  526. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    Performance of sentinel lymph node (SLN) mapping in high-risk endometrial cancer.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31338.
    PubMed     Text format     Abstract available


  527. SHAH JS, Guerra R, Bodurka DC, Sun CC, et al
    Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31343.
    PubMed     Text format     Abstract available


  528. BARBER EL, Rossi EC, Gehrig PA
    Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31340.
    PubMed     Text format     Abstract available


  529. DO JH, Choi KH, Ahn JS, Jeon JY, et al
    Effects of a complex rehabilitation program on edema status, physical function, and quality of life in lower-limb lymphedema after gynecological cancer surgery.
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31272.
    PubMed     Text format     Abstract available


  530. RUSTIN G, Vergote I, Micha JP, Duska LR, et al
    A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31264.
    PubMed     Text format     Abstract available


  531. MOORE KN, Tritchler D, Kaufman KM, Lankes H, et al
    Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31261.
    PubMed     Text format     Abstract available


  532. LEE SW, Lee SH, Kim J, Kim YS, et al
    Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KROG 16-01.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31265.
    PubMed     Text format     Abstract available


  533. TANGEN IL, Veneris JT, Halle MK, Werner HM, et al
    Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31337.
    PubMed     Text format     Abstract available


  534. DANTAS PRS, Maesta I, Filho JR, Junior JA, et al
    Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31310.
    PubMed     Text format     Abstract available


  535. RAUH LA, Pannone AF, Cantrell LA
    Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care?
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31333.
    PubMed     Text format     Abstract available


  536. GEBHARDT B, Gill B, Glaser S, Kim H, et al
    Image-guided tandem and cylinder brachytherapy as monotherapy for definitive treatment of inoperable endometrial carcinoma.
    Gynecol Oncol. 2017 Sep 15. pii: S0090-8258(17)31309.
    PubMed     Text format     Abstract available


  537. AZAIS H, Ghesquiere L, Petitnicolas C, Borghesi Y, et al
    Pretherapeutic staging of locally advanced cervical cancer: Inframesenteric paraaortic lymphadenectomy accuracy to detect paraaortic metastases in comparison with infrarenal paraaortic lymphadenectomy.
    Gynecol Oncol. 2017 Sep 14. pii: S0090-8258(17)31334.
    PubMed     Text format     Abstract available


  538. BINDER PS, Kuroki LM, Zhao P, Cusworth S, et al
    Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer.
    Gynecol Oncol. 2017 Sep 12. pii: S0090-8258(17)31269.
    PubMed     Text format     Abstract available


  539. LILYQUIST J, LaDuca H, Polley E, Davis BT, et al
    Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
    Gynecol Oncol. 2017 Sep 7. pii: S0090-8258(17)31268.
    PubMed     Text format     Abstract available


  540. PISU M, Kenzik KM, Rim SH, Funkhouser EM, et al
    Values and worries of ovarian cancer patients.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31267.
    PubMed     Text format     Abstract available


  541. COWAN RA, Tseng J, Murthy V, Srivastava R, et al
    Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31270.
    PubMed     Text format     Abstract available


  542. SCHLUMBRECHT M, Baeker Bispo JA, Balise RR, Huang M, et al
    Variation in type II endometrial cancer risk by Hispanic subpopulation: An exploratory analysis.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31271.
    PubMed     Text format     Abstract available


  543. HUO D, Anderson D, Palmer JR, Herbst AL, et al
    Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up.
    Gynecol Oncol. 2017;146:566-571.
    PubMed     Text format     Abstract available


  544. POUWER AW, Hinten F, van der Velden J, Smolders RGV, et al
    Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study.
    Gynecol Oncol. 2017;146:580-587.
    PubMed     Text format     Abstract available


  545. RAO YJ, Chin RI, Hui C, Mutch DG, et al
    Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database.
    Gynecol Oncol. 2017;146:572-579.
    PubMed     Text format     Abstract available


  546. LOPEZ LABROUSSE MI, Frumovitz M, Guadalupe Patrono M, Ramirez PT, et al
    Sentinel lymph node mapping in minimally invasive surgery: Role of imaging with color-segmented fluorescence (CSF).
    Gynecol Oncol. 2017;146:676-677.
    PubMed     Text format     Abstract available


    May 2017
  547. ARGENTA PA
    Attacking obesity-related diseases at the source - Is bariatric surgery the next wave in cancer prevention?
    Gynecol Oncol. 2017;145:219-220.
    PubMed     Text format    


    April 2017
  548. BOULAY E, Galczynski K, Canis M, Bourdel N, et al
    Laparoscopic pelvic lymphadenectomy in 10 steps - let's make it easier!
    Gynecol Oncol. 2017;145:217-218.
    PubMed     Text format    


    January 2017
  549. KIM HS, Lee M
    Video endoscopic inguinal lymphadenectomy (VEIL) for vulvar cancer.
    Gynecol Oncol. 2017;144:225-226.
    PubMed     Text format    


    April 2016
  550. NAROD SA
    Talc and ovarian cancer.
    Gynecol Oncol. 2016 Apr 16. pii: S0090-8258(16)30139.
    PubMed     Text format    


  551. ALVAREZ RD, Matulonis UA, Herzog TJ, Coleman RL, et al
    Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
    Gynecol Oncol. 2016 Apr 3. pii: S0090-8258(16)30063.
    PubMed     Text format    


    February 2016
  552. NAROD SA, Sopik V, Giannakeas V
    Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Gynecol Oncol. 2016 Feb 25. pii: S0090-8258(16)30044.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: